






























































































 ABSTRACT HIV‐1  infection  remains  a  major  crisis  in  sub‐Saharan  Africa  and  more  information about disease pathogenesis and  immune correlates of protection are needed. Uganda, with a population of approximately 33 million people, has a national HIV‐1 prevalence over  6%  with  subtype  A  and  subtype  D  predominating.  We  aimed  to  characterize immune cell functions in Ugandans with untreated chronic HIV‐1 infection, and identify aspects of the immune response that are associated with control of viremia and disease progression.  As  this  work  was  based  on  stored  specimens  from  cohorts  in  the  rural districts of Kayunga and Rakai, we  first detailed  the  importance of  rigorous protocols for  quality  PBMC  cryopreservation  in  the  resource  limited  setting  in  Paper  I. Importantly,  cryopreservation did not  compromise  relative  frequencies or  function of PBMCs, and long‐term storage of samples for greater than 3 years did not impact yield or viability. We developed a program to monitor PBMC processing to ensure suitability for the studies of adaptive and innate immunity included in this thesis. In Paper II, we found redistribution of NK cell subsets, with increase in CD56neg NK cells and reduction of CD56dim NK cells, in HIV‐1 infected Ugandans. Moreover, we observed decreased NK cell expression of KIR2DL1, NKG2A, CD161 and NKp30 in these patients. Interestingly, severe  loss  of  CD4 T  cells was  associated with  elevated  levels  of  KIR  expression  and degranulation in CD56bright NK cells, suggesting that cytotoxic function develops in this subset in progressive HIV disease. In Paper IV, we continued to build on these findings and  discovered  a  preferential  expansion  of  KIR3DL1+  NK  cells  that  was  directly proportional  to  HIV‐1  viral  load  in  donors  that  possessed  the  HLA‐B  Bw4‐80I motif. Other inhibitory KIRs were reduced or remained constant in the presence of their HLA ligands.  Overall,  NK  cells  in  HIV‐1  infected  Ugandans  displayed  an  elevated  activity despite an altered functional and phenotypic profile in chronic disease. Additionally, NK cells in these patients were more polyfunctional with regard to CD107a, IFN‐γ, and MIP‐1β  expression  as  compared  to  uninfected  controls.  The  KIR3DL1+  NK  cells  in  Bw4+ individuals  were  particularly  responsive,  producing  increased  IFN‐γ  and  MIP‐1β.  In 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FOREWORD Throughout my studies and professional career, the HIV/AIDS epidemic has driven and stimulated  scientific  advancement  to  better  understand  the  intricacies  between  host and pathogens. A safe and effective HIV vaccine  is desperately needed and  the search continues.  Over  the  past  14  years  I  have  participated  in  HIV  trials  and  cohort development via technical support and immunogenicity evaluation of several products and natural history protocols. As an employee of the US Military HIV Research Program (MHRP),  I  have  experienced  the  challenges  of  conducting  human  studies  and understand  the  paramount  need  to  discover  correlates  of  protection.  Our understanding of immune response manipulation through HIV vaccination continues to expand with every clinical trial that is conducted. In 2003, I moved to Kampala, Uganda, where  I  was  responsible  for  development  of  PBMC  processing  and  immunological studies  for  the Makerere University Walter Reed Project  (MUWRP), part of  the MHRP network. Living in Uganda, I witnessed a different perspective on the impact of HIV on the population and the  foundation of society. Here,  I was able  to study T‐cell  immune responses to DNA and adenovirus vaccine platforms developed by the Vaccine Research Center, National Institutes of Health. In addition to human clinical trials, natural cohort studies have provided a crucial understanding of how HIV‐1 interacts with our immune system. It is here that I began a new chapter in my life.  In 2007, I entered into a PhD program through the Center for Infectious Medicine, at the Karolinska  Institutet  in  Stockholm,  Sweden,  and  through  a  tri‐continent  coalition  the studies  mentioned  in  this  thesis  were  outlined  and  executed.  This  collaborative initiative began by describing the importance of PBMC processing and means to ensure quality  in  order  to  support  downstream  immunological  assessment.  More  recently  I have  investigated  how  the  innate  immune  population  of  NK  cells  respond  during chronic HIV‐1 infection and continue to explore activating and inhibitory receptors with intense  interest  in  KIRs  and  their  HLA  ligands.  Harnessing  this  innate  effector population may help vaccine design and development. Through our cohorts, a number of studies were carried out on T cells as well. This thesis will discuss the aberrant T cell activation that has been intimately associated with HIV‐1 disease progression. It is my hope  that  the  studies  below  will  not  only  provide  additional  insight  into  the  HIV‐1 epidemic in Uganda with regard to cellular immunity, but also generate new ideas and hypothesis to test in future studies.  I am now living back in the US and working at the MHRP in Rockville, Maryland. Within the  Department  of  Vaccine  Research  and  Development  there  is  an  excitement  and  a sense  of  urgency  to  capitalize  on  the  recent  Thai  phase  III  RV144  trial  and  identify possible correlates of protection. The work I have completed in Africa, Sweden and the US has allowed me to broaden my horizons, establish collaborations and help develop my  career  as  an  independent  research  scientist  in  the  search  for  a  correlate  of protection for HIV.   Michael A. Eller                          Stockholm, April 2, 2011
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ABBREVIATIONS Ad5  adenovirus serotype 5 ADCC  antibody dependent cellular cytotoxicity AIDS  acquired immune deficiency syndrome ART  anti‐retroviral therapy AZT  azidothymidine CCR7  CC chemokine receptor 7 CD  cluster of differentiation or cluster of designation CDC  Centers for Disease Control CFSE  carboxyfluorescein diacetate succinimidyl ester CMV  cytomegalovirus CTL  cytotoxic T lymphocyte CTLA  cytotoxic T lymphocyte antigen EBV  Epstein‐Barr virus DAMP  danger associated molecular patterns DC  dendritic cell FACS  fluorescence‐activated cell sorting  FasL  Fas ligand FOXP3  forkhead box protein 3 GALT  gut associated lymphoid tissue HAART  highly active anti‐retroviral therapy HEV  high endothelial venules HIV  human immunodeficiency virus HLA  human leukocyte antigen HPV  human papillomavirus ICOS  inducible T cell costimulator IFN  interferon IL  interleukin ITAM  immunoreceptor tyrosine‐based activating motif  ITIM  immunoreceptor tyrosine‐based inhibitory motif  ITSM  immunoreceptor tyrosine‐based switch motif  KIR  killer cell immunoglobulin‐like receptors LAMP  lysosomal‐associated membrane protein LFA  lymphocyte function associated antigen LPS  lipopolysaccharide MALT  mucosal associated lymphoid tissue MHC  major histocompatibility complex MIP  macrophage inflammatory protein NCAM  neural cell adhesion molecule NCR  natural cytotoxicity receptors NK  natural killer NOD  immunoreceptor tyrosine‐based inhibitory motif PAMP  pathogen associated molecular patterns PBMC  peripheral blood mononuclear cells PD‐1  programmed death receptor‐1 pDC  plasmacytoid dendritic cell 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1.1 Overview In  2008,  two  French  scientists  were  selected  by  the  Karolinska  Institutets  Nobel Assembly  to  be  awarded  half  of  the  Nobel  Prize  in  Physiology  or  Medicine  for  their identification  of  the  virus  that was  later  shown  to  cause  acquired  immune deficiency syndrome  (AIDS).  In  this  seminal  work  by  Francoise  Barre‐Sinoussi  and  Luc Montagnier, a new retrovirus was isolated from a patient’s lymph node that had similar features to a family of viruses known as human T‐cell leukemia viruses1. A subsequent study in the US, lead by the efforts of Robert Gallo, found that in a significant number of patients with symptoms that precede AIDS or  in patients with AIDS defining  illness, a virus  he  and  colleagues  named  human  T‐lymphotropic  retrovirus  III  (HTLV‐III)  was frequently  isolated  from  peripheral  blood  lymphocytes  supplemented  with  T  cell growth  factor2. From these pivotal  studies and subsequent work,  it became clear  that the virus we now know as the human immunodeficiency virus (HIV), was the cause of AIDS. This disease was first characterized in homosexual men and drug users between 1979 and 1981 who acquired Pneumocystis carinii Pneumonia and was associated with an  immune  dysfuntion3.  Over  the  next  three  decades,  scientists  made  significant progress  in  immunology,  virology,  and  through  technical  advancement  our understanding of HIV‐1 has grown. Despite the enormous efforts around the globe, HIV and AIDS has become one of the worst epidemics of all time.  Currently, there are over 33 million people living with HIV‐1 while an estimated 1.8 million people die each year from AIDS  related  illness. Almost  two‐thirds  of  this  pandemic  resides  in  Sub‐Saharan Africa, a setting limited in the resources necessary to combat the disease4.  
1.2 HIV­1 virology HIV‐1  is  a  single  stranded,  positive‐sense  enveloped  RNA  virus  from  the  family Retroviridae,  subfamily Orthoretroviridae. HIV‐1 virions are spherical and 80‐110 nm in diameter  encased by  a  lipid‐containing  envelope with  glycopeptide  spikes  8  nm  in length  that  surround  an  icosohedral  shaped  capsid. HIV‐1’s RNA genome  is  relatively small,  approximately  9  kilobases,  and  encodes  for  14  proteins  including  3  structural proteins, 2 envelope proteins, 6 accessory proteins, and 3 enzymes all of which facilitate entry, reverse transcription, integration and replication within the host’s cells5. Figure 1 summarizes  the  complete  replication  cycle  of  HIV‐1.  The  first  step  in  the  replication cycle  of  HIV‐1  is  binding  and  entry  into  the  target  cell  through  the  cluster  of differentiation  (CD)4  receptor,  first  characterized  on  a  subset  of  T  cells6,7.  Other  cell types such as dendritic cells (DC) and macrophages have been shown to be infected and could play a crucial role in viral dissemination, particularly in the case of DC8‐11. HIV‐1 binds  the  CD4  receptor,  a  surface  glycoprotein,  resulting  in  a  conformational  change that allows co‐receptor binding, membrane fusion and injection of the viral capsid into the  cytosol12.  Once  inside  the  cell,  HIV‐1’s  RNA  genome  is  reverse  transcribed  into double stranded DNA by the viral enzyme reverse transcriptase (RT) and is transported inside the nucleus where the integrase enzyme incorporates the viral DNA into the host DNA  thereby  establishing  infection13.  The  proviral  DNA  can  remain  latent  or  upon activation,  polymerase  II  can  initiate  the  transcription  and  creation  of  mRNA transcripts. The transcripts are targeted out of the nucleus to various compartments in 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the cytosol where they are translated and transported to the cell surface for assembly5.  Immature virions bud  from the surface of  the cell enveloped  in host  cell  lipid bilayer, other  surface  receptors,  and  viral  glycoprotein  spikes,  then,  finally  mature  into infectious virions13.   
 
Figure 1. HIV­1 Replication Cycle (adapted from Ganser­Pornillos, B.K. et al., 2008)13.  The  origin  of HIV  is  thought  to  have  occurred  from human  contacts with non‐human primates in Africa. HIV‐1 and HIV‐2 represent two separate cross‐species transmissions from  the  common  chimpanzee  (Pan  troglodytes  troglodytes)  and  sooty  mangabey (Cercocebus  atys)  respectively,  based  on  HIV  phylogenetic  lineage  characterization14. HIV‐2 is less prevalent compared to HIV‐1, is less efficiently transmitted and results in a slower disease progression15. HIV‐1 is the virus responsible for the global pandemic and has a high rate of replication, transcriptional error and recombination, resulting in great genetic  diversity  throughout  the  world.  Phylogenetic  analysis  identifies  three  major groups of HIV‐1 labeled as M, N, and O, where group M represents the main group with the  greatest  number  of  variations  that  are  clustered  together  into  distinct  lineages called subtypes or clades16. There are 9 known subtypes of HIV‐1 group M virus, A‐D, F‐H,  J‐K and a growing number of  recombinant  forms are developing around  the world that  further  contribute  to  the  global  diversity  of  HIV‐117.  HIV‐1  subtype  B  is predominant in the US and Europe, subtype AE is found in southeast Asia, subtype A, C and  D  are  most  common  in  East  Africa  while  infections  in  South  Africa  are predominantly  subtype  C.  Globally,  subtype  C  is  the  most  prevalent,  accounting  for about  50%  of  infections18.  Another  way  to  classify  virus  is  based  upon  coreceptor utilization.  The  primary  coreceptors,  CXCR4  and  CCR5,  are  able  to  classify  virus  as macrophage  infecting  (M‐tropic),  T  cell  infecting  (T  tropic)  or  both  (dual  tropic) 
 6 
(reviewed  in19).  The  extreme  diversity  of  HIV‐1  contributes  to  the  difficulty  in development of measures to prevent acquisition of this virus.  





1.4 HIV­1 treatment and prevention After  the  identification  of  the  virus  that  causes  AIDS,  extraordinary  scientific  efforts were  made  to  develop  diagnostic  techniques  to  detect  infection  and  understand  the replication cycle of HIV‐1 in order to identify potential therapeutic targets that mitigate the  disease.  Early  clinical  trials  tested  azidothymidine  (AZT),  a  nucleoside  analog reverse  transcriptase  inhibitor  that  was  effective  in  reducing  HIV‐1  viral  load,  but despite  the  initial  success,  patients  quickly  developed  drug  resistant  strains  to  this monotherapy15.  Additional  pharmaceuticals  such  as  protease  inhibitors,  alternative reverse  transcriptase  inhibitors,  integrase  inhibitors,  and  cell  entry  inhibitors  were designed and developed to interrupt different stages of the HIV replication cycle.  These drugs, when  used  in  combinations  of  three  or more, were  termed  highly  active  anti‐retroviral  therapy  (HAART)  and  proved  to  be  a  much  more  effective  treatment regimen24. HAART became widely available to HIV‐1 infected patients in countries that could afford the high cost of these drugs and more recently have been made available in resource‐limited  settings.  HAART  reduces  HIV‐1  viral  load  upon  treatment  initiation and gradual increases in CD4+ T cells are observed throughout successful therapy. The use of HAART has reduced AIDS related deaths, but there is continued debate over how early  to  initiate  treatment as some studies suggest  that earlier  treatment  intervention leads to better outcomes27. However, the benefits of initiating HAART during acute HIV‐1 infection are unclear28,29. HAART is not without limitations. Some individuals continue to  experience  CD4+  T  cell  decline  despite  successful  viral  suppression  potentially caused  by  the  irreversible  damage  to  the  T  cell  compartment  in  early  infection30.  In addition,  drug  toxicities,  side  effects  and  cost  are  hurdles  that  need  to  be  overcome. Despite  the  clear  evidence  that  starting  patients  on  HAART  early  is  beneficial,  this 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remains  a  daunting  task  in  settings  where  access  to  these  life  saving  drugs  remain inadequate.  Alternative  strategies  to  prevent  the  acquisition  of  HIV‐1  are  urgently needed, as we may not be able to treat our way out of this epidemic31‐33.  A number of measures have been explored in order to prevent the acquisition of HIV‐1, with the ultimate goal of a safe and effective vaccine. Many challenges and hurdles have plagued  these  efforts,  but  several  successes  have  also  been  realized  over  the  past decade. One major prevention strategy was to educate and alter behaviors  in order to reduce HIV‐1 incidence. The ABC’s were an example of teaching people to “A” ‐ abstain from sex, “B” ‐ be faithful to your partner, and “C” use condoms. It  is hard to measure the  success of  such prevention  strategies, but  this message  remains a  central mantra, particularly  in  Africa  where  the  rate  of  new  infections  exceeds  the  rate  of  patients initiating treatment15. Medical male circumcision is another approach to prevent HIV‐1 infection  and  three  randomized,  controlled  trials  in  Africa  exhibited  a  reduction  in transmission of 53% ‐ 60% in men undergoing the surgical procedure34‐36. However, the long‐term  population  effect  of  male  circumcision  remains  conjecture  and  rolling  out widespread surgical interventions in Africa presents an enormous challenge37.     The  most  desired  prevention  method  for  the  majority  of  infectious  diseases, vaccination, had proven not only unsuccessful in the HIV‐1 field, but also unlikely, until a  groundbreaking  proof  of  concept  trial  in  2009.  A  community  based  randomized, double‐blind, placebo‐controlled efficacy trial of HIV‐1 canarypox vector prime, boosted with  recombinant  glycoprotein  120  (gp120)  subunit  vaccine  in  Thailand  exhibited  a modest and transient efficacy in protecting trial participants38. While the results of the RV144 trial demonstrated that an HIV‐1 vaccine is possible, the field is still years away from  developing  a  product  that  is  ready  for  mass  distribution.  In  2010,  another randomized  prevention  trial  provided  a  new  weapon  into  our  arsenal  for  HIV‐1 prevention. Pre‐exposure of men who have sex with men with a daily regimen of  two antiretroviral  drugs,  emtricitabine  and  tenofovir  disoproxil  fumarate,  showed  a  44% reduction  in  HIV‐1  acquisition39.  While  these  results  are  promising,  a  number  of concerns  remain  with  long‐term  adherence,  drug  toxicities,  and  drug  resistant acquisition40.  Taken  together,  our  HIV‐1  prevention  repertoire  remains  limited  and underscores  the  need  for  a  better  understanding  of  the  complex  interaction  between host and virus in order to reduce HIV‐1 incidence through more targeted interventions. 
 
1.5 HIV­1 in Uganda – The Pearl of Africa While the first reports of HIV‐1 and AIDS were focused on men who have sex with men and  intravenous  drug  users  in  the  US  and  Europe,  a  completely  different  story  was unfolding in Africa. Uganda, an Eastern African country west of Kenya and nestled atop Lake  Victoria  is  approximately  250,000  square  km  with  a  population  of  over  33 million41.  In  1985,  David  Serwadda  and  colleagues  published  an  article  in  Lancet characterizing  “Slim  Disease”  in  the  southwestern  district  of  Rakai,  Uganda42.  In  this article,  a  new  disease  associated  with  promiscuous  heterosexual  patients  presenting with  abnormal  and  prolonged  weight  loss,  diarrhea,  oral  candidiasis,  and  other opportunistic  infections was  associated with what was  later named HIV‐1. Unlike  the previous reports in the west, this disease was not associated with homosexual behavior and did not have the same prevalence of Kaposi sarcoma, and therefore was suspected 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as being of unique origin. More knowledge and awareness regarding the HIV‐1 epidemic followed  and  a  national  hospital  based  surveillance  system  showed  that  this  was  a disease of men and women primarily aged 15‐42 years with most showing symptoms of weight  loss,  fever,  diarrhea,  cough,  and  rash43.  HIV‐1  prevalence  was  shown  to  be approximately  28%  in  1991  and  confirmed  a  widespread  epidemic44.  Through education and modification to sexual behavior, Uganda was considered a major success story as the HIV‐1 prevalence rates dramatically reduced to a reported 12% in 199745, however a number of investigators caution about over interpreting the reasons for the decline46,47.  Uganda  quickly  developed  infrastructure  to  study  HIV‐1  natural  history cohorts  in  order  to  better  understand  the  dynamics  of  HIV‐1  infection  in  the community48,49.  Uganda  continues  to  make  progress  with  regards  to  lowering  the national  prevalence of HIV‐1  as more  recent  reports  estimate 6.4% of  the population are HIV‐1 infected50 but data exists that HIV‐1 could be on the rise again51. The HIV‐1 epidemic  in  Uganda  has  evolved  and  additional  prevention  strategies  are  needed  to reduce the number of new infections while treatment scale‐up continues.  Early on, Uganda embraced research on prevention strategies to combat HIV‐1 and the community responded by participating in a number of pivotal studies that have helped shape  the  understanding  of  the  disease.  Uganda  was  the  first  African  country  to participate  in  a  preventative  HIV‐1  vaccine  trial.    An  HIV‐1  canary  pox  vaccine  was tested for safety in a group of 40 HIV‐1 uninfected Ugandans, and was determined to be safe  and  mildly  immunogenic52.  This  opened  up  testing  of  many  preventative  HIV‐1 vaccine  strategies  such  as  DNA  alone53,  in  combination  with  modified  vaccinia  virus Ankara  (MVA)54,  or  in  combination with  recombinant  adenovirus  serotype  5  (Ad5)55. While  these  trials  demonstrate  increased  capacity  to  conduct  clinical  research  in Uganda,  the  collective  results  show  little  advancement  towards  an  effective  vaccine.  Another prevention strategy, a medical male circumcision trial in 4,996 uncircumcised men  in  Rakai  District,  Uganda  showed  55%  efficacy36.  The  community  in  Rakai continues to  investigate the potential benefits of circumcision on transmission studies of human papillomavirus (HPV) from men to uninfected women where female partners of circumcised males were at lower risk to contract HPV 56. Another study failed to show any effect of medical male circumcision of HIV‐1 infected men to their uninfected female partner57.  While  circumcision  provides  some  protection,  Uganda  currently  lacks  the infrastructure to support widespread implementation in the general population. Other interventions have been explored in at risk populations such as children born to HIV‐1 infected mothers. Uganda has participated in studies to prevent vertical transmission of HIV‐1  using  administration  of  the  antiretroviral  drugs  AZT  in  combination  with lamivudine58 or comparing AZT to nevirapine59. While the results of these studies show reduction  in  mother  to  child  transmission,  the  issue  of  transmitting  drug  resistant strains  of  HIV‐1  remains  a  concern60.  Uganda  has  participated  in  a  plethora  of  other clinical studies and has demonstrated that the people of Uganda are willing to take part in the study of diseases relevant to the population. 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Figure 3. Map of Uganda.  In addition to human clinical  trials, Uganda has shown great prowess and progress  in developing the infrastructure to conduct basic scientific research and diagnostic testing due to the HIV‐1 epidemic. Several studies examined more efficient and reliable ways to diagnose  HIV‐1  infection  using  rapid  platforms61,62.  Furthermore,  technology  to characterize the molecular epidemiology has shed light on the viral diversity in Uganda, which may impact disease progression and can complicate development of preventative and  therapeutic  interventions63‐66.  There  is  also  a  growing  ability  to  conduct sophisticated  immunology  studies  in  the  context  of  both  vaccine  immunogenicity52‐55 and HIV‐1 natural cohort studies 67‐71. Taken together, Uganda has made extraordinary advancement  in  the  face  of  adversity  by  embracing  the  research  and  development surrounding  infectious  diseases,  in  particular  HIV‐1.  Despite  these  efforts,  more information is required about factors driving disease and the host responses associated with more  favorable outcomes  that could be replicated or harnessed  through modern medicine.  Understanding  the  human  immune  system  and  the  cells  that  mediate infection control could provide crucial insight into these matters. 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2. THE HUMAN IMMUNE SYSTEM  
2.1 Overview  Since the beginning of life, organisms have competed for the precious resources on this planet to sustain their existence and evolution facilitated the development of a range of complex systems that favor one organism over another. In fact, Charles Darwin’s theory of  natural  selection  depicted  a  situation  where  individuals  with  favorable characteristics  would  breed  and  survive  while  those  organisms  with  less  favorable characteristics would  struggle  for  existence72.  This holds  true  for  the human  immune system. Put simply, immunology is the study of the body’s defense against infection. The human  immune  system  has  evolved  to  incorporate  a  number  of  strategies  to  protect from “enemies both foreign and domestic” (US Armed Forces OATH OF ENLISTMENT), and  like  any  army,  has  an  arsenal  at  its  disposal.  The  foreign  invaders we  encounter include  bacteria,  fungi,  parasites,  and  viruses,  which  are  constantly  trying  to  break through our barricades to  infect and compete for our resources while domestic  issues arise  such  as  autoimmunity,  hypersensitivity,  immune  deficiencies  and  tumors.  All human  immune components can trace back  to  lower  level organisms;  in  fact all  living organisms have what some would argue is a level of immune response. For example, the amoeba, which  predates  eukaryotic  cells  by  billions  of  years, may  be  the  ancestor  of modern  phagocytosis,  a major  component  of  immunity  employed  by macrophages  or other  antigen  presenting  cells which  engulf  and  digest  pathogens73.  Another  example would  be  the  toll‐like  receptors  (TLRs),  which  are  specialized  receptors  able  to recognize certain pathogen associated molecular patterns (PAMPs) and were named for their  resemblance  of  a  protein  coded  for  by  the  toll  gene  in  the  fruit  fly  (genus 
Drosophila).    Recently,  a  TLR  was  reported  in  sponges  (Suberites  domuncula)  that recognize  bacterial  lipopolysaccharide  (LPS), which  signifies  that  this  innate  immune receptor and mechanism has been around  for approximately 800 million years74. The fact  that many components of  the human  immune system have ancestral homologs  in other organisms is not surprising, but puts in context the time frame and evolutionary impact  that  has  selected  for  the  complexity,  diversity  and  ability  to  deal with  a wide range of pathogens and disease.    Immunology  is  classically  a  dichotomous  field,  segregating  components  into  polar groups  such  as  innate  versus  adaptive,  cellular  versus  humoral,  self  versus  non‐self, lymphoid  versus  myeloid,  and  so  on.  To  this  extent,  we  may  oversimplify  or misinterpret  the  gray  area  in  between many of  these  groups. As we develop  a  better understanding  of  the  function  and  phenotype  of  particular  responses,  we  can  form better models that connect the bi‐polar nature of immunology. However, it is important to break things down to understand how each component works and then try to put it together to see how the pieces integrate. The human immune system has 4 components that are responsible for protecting the host from disease: recognition, effector functions, regulation and memory75.  There exist many components to the immune system such as cells, proteins,  chemicals,  and even physical barriers.  Important  in  immunology  is  the ability to recognize a foreign pathogen or define danger while being able to discriminate and protect “self” and this is accomplished through specialized receptors on the surface of  cells  of  the  immune  system.  The  components  of  the  immune  system  are  grouped 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based on specific or nonspecific recognition, which corresponds to adaptive and innate immunity  respectively.  Innate  immunity  is  an  immediate  response  of  cells  with  a repertoire  of  specialized  pattern  recognition  receptors  (PRR)  specially  designed  to recognize  PAMPs  and  contain  infection.  The  adaptive  immune  response  results  from initial  exposure  to  a  pathogen  leading  to  the  stimulation  and  priming  of  a  naïve  cell highly  specific  for  that  pathogen  followed  by  expansion  and  development  of immunologic memory. Upon re‐exposure, the adaptive immune system can contain and eliminate  the  pathogen  with  greater  efficiency.  The  interplay  between  infection  and immune  response  is  intricate  and  it  is  important  to understand how  the  cells of both innate  and  adaptive  arms work  to  better  define  how  immune  responses  develop  and what may be critical to provide protection from disease.  
2.2 Innate immunity Innate immunity consists of germline encoded, non “antigen‐specific” cells that are able to respond to a diverse range of PAMPs in a quick and broad effort to clear infection or provide  control  until  the  adaptive  immune  response  can  support  and  clear  the pathogen.  A  number  of  innate  mechanisms  have  evolved  to  deal  with  the  infectious burden  that we  constantly  encounter. The  innate  immune  response  is  comprised of  a number  of  cells  including  DC,  granulocytes,  macrophages,  monocytes,  natural  killer (NK) cells, and others that do not undergo clonal expansion or receptor rearrangement in  order  to  recognize  particular  antigens.  These  cells  can  respond with  a  number  of effector  functions  such  as  phagocytosis,  production  of  cytokines  and  chemokines  and direct  killing.  In  addition  to  recognition of  extracellular pathogens or  foreign  antigen, the innate immune compartment can recognize warning signals from within the cell or danger  associated  molecular  patterns  (DAMPs)  and  trigger  inflammatory  responses. For  example,  the  NOD  (nucleotide‐binding  oligomerization‐domain  protein)‐like receptor NALP3 can recognize signals such as bacterial RNA and LPS. However, NALP3 can also recognize certain reactive oxygen species or other DAMPs which activate IL‐1b via  caspase‐1,  and  in  turn  stimulate  production  of  IL‐6,  thereby  increasing  the inflammatory environment76.   The acute  inflammation process, driven by mechanisms such as NALP3, recruits cells and soluble factors to restrict access to the site, eliminates the  infectious  agent  and  repairs  damage  to  the  local  environment77.  Tissues  that  are more  likely  to encounter pathogens are staffed with populations of  immune cells  that are  poised  to  respond,  such  as  DCs,  which  enact  several  functions  including  antigen capture,  antigen  presentation  and  cytokine/chemokine  production.  One  subset  of DC, the  plasmacytoid  DC  (pDC),  are  specialized  to  produce  copious  amounts  of  type  I interferons  when  challenged  with  various  viruses78.  Interestingly,  interferons  are classically  defined  as  viral  inhibiting  cytokines  but  are  associated  with  both  anti‐inflammatory  and  pro‐inflammatory  conditions79.  Another  cell  of  importance  in  the innate  immune  response  is  the  NK  cell,  which  distinguishes  normal  and  altered conditions  through  a  multiplexed  system  of  activating  and  inhibitory  receptors.  The innate immunity portion of this thesis will focus on the NK cell phenotype and function in healthy and HIV‐1 chronically infected Ugandans.  
2.3 NK cells, receptors and function NK cells were first reported  in 1975 by two independent research groups working on cancer,  where  normal  murine  lymphoid  cells  were  able  to  kill  syngeneic  as  well  as 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allogeneic tumors from mice without prior sensitization80‐83. This represented a major paradigm  shift  as  effector  lymphocytes  were  presumed  to  be  T  cells  and  operate  by antigen  exposure  and  recognition  in  a  highly  specific manner.  In  fact,  early  data was initially thought to be experimental artifact, and natural cytotoxicity was dismissed by some as merely noise in the chromium release assay used to measure suppressor T cell responses84.  Despite  the  initial  skepticism,  NK  cells  have  since  been  shown  to  be  a significant  population  of  large  and  granular  effector  cells,  numbering  up  to  15%  of circulating  lymphocytes,  with  a  wide  range  of  functions  and  utility.  Approximately  2 billion NK cells are circulating throughout the body at any given time, descending from a  common  lymphoid  progenitor  cell  and  ultimately  differentiating  from  CD34+ hematopoetic  stem  cells  in  the  bone  marrow85.  It  is  unclear  where  NK  cell differentiation occurs, as NK progenitors have been isolated from the bone marrow and thymus, but there appears to be a requirement for proliferative cytokines as these NK cell precursors express CD122, the common β chain for IL‐2 and IL‐15 and require these cytokines to differentiate in vitro86,87. NK cell precursors can be found in the secondary lymphoid  tissues,  such  as  lymph  nodes  and  mucosal  associated  lymphoid  tissues (MALT), where  cells  identified  as  CD34+  CD45RA+ NK  cell  precursors were  found  in areas associated with DCs expressing high amounts of membrane bound IL‐1585. While our understanding of NK cell development is not complete, the presence of these cells in a wide range of tissues implicates their importance in a number of immune functions. In addition, a number of  clinical  cases associated with an aberrant NK cell  compartment have shed insight into the role of NK cells in disease as well as identifying some of the critical  pathways  of  a  cytotoxic  NK  cell88. While  not  common,  NK  cell  deficiencies  in humans are associated with immune dysfunction and lack of control of bacterial, fungal and  viral  pathogens  in  particular  herpes  viruses  that  in  several  cases  prove  fatal88. While many of  the genetic or acquired conditions  that result  in NK cell  loss or  loss of function are not unique to NK cells, it is clear that these cells are a central component to the human immune system.  Since  the  discovery  of  NK  cells  over  35  years  ago,  a  growing  body  of  data  is accumulating  regarding  the  complexity  of  how  these  cells  detect  danger  or  stress.  In 1985  and  1986,  two  revolutionary  papers  redefined  basic  immunology  principles  by proposing  that  NK  cells  might  recognize  or  sense  missing  major  histocompatibility complex (MHC) molecules on the surface of cells as an alternative immune strategy89,90. In 1981, Klas Kärre, a doctoral student at the Karolinska Institutet, originally proposed this  theory  later  called  the  “missing  self”  hypothesis  in  the  final  chapter  of  his  PhD thesis91.  We  now  understand  that  viruses  and  tumors  have  evolved  mechanisms  to evade the adaptive T cell immune response by reducing the level of MHC molecules on the surface of cells  in order to escape detection. NK cells are able to sense the altered expression  of  MHC  and  kill  those  cells  through  a  number  of  receptors  designed  to monitor  human  leukocyte  antigen  (HLA),  in  addition  to  a  number  of  other  receptors that  regulate  their  function. The NK cell array of  stimulatory and  inhibitory receptors includes:  killer  cell  immunoglobulin‐like  receptors  (KIRs),  C‐type  lectin  receptors, natural  cytotoxicity  receptors  (NCRs),  and  TLRs92,93  (Figure  4).  As  a  matter  of convention and  lack of NK cell specific or universal NK markers,  two cellular markers are used to identify and characterize human NK cells. CD56 is the neural cell adhesion 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molecule  (NCAM)  and CD16  is  the  Fcγ‐receptor  IIIa, which  is  the  low affinity  binding receptor  that  recognizes  the  Fc  portion  of  IgG  antibodies.  CD56  and  CD16  flow cytometric  staining  intensities  segregate  NK  cells  into  two  functional  subsets, immunomodulatory  and  cytotoxic with CD56brightCD16+/‐  representing  the  former  and CD56dimCD16+/‐  representing  the  later  and most  substantial  subset  (up  to  90% of NK cells)85,94,95.  A  third  subset  characterized  as  CD56negCD16+  has  also  been described  in the literature96 and will be discussed later in this thesis. It is important to mention that the  receptors  found  on  the  various  subsets  of  NK  cells  are  also  found  on  other lymphocyte lineages and only the NCRs are thought to be restricted to NK cells.  The KIRs represent a group of activating and inhibitory receptors that may regulate the immune  response  to  pathogens  or  cellular  transformations.  There  are  17  KIR  genes coding for 9 inhibitory receptors, 6 activating receptors, and 2 pseudogenes that are not expressed97,98. Over 30 KIR haplotypes exist  that can be divided  into groups based on absence  (haplotype  A),  or  presence  (haplotype  B)  of  activating  KIRs99.  Several  MHC class  I  molecules  are  ligands  for  certain  KIRs  and  a  growing  interest  has  developed surrounding these interactions, because KIR and HLA genes are highly polymorphic and certain  KIR‐HLA  interactions  may  influence  disease  outcomes100.  KIR3DL1,  and probably  also  KIR3DS1,  recognize  HLA  Bw4  allotypes  with  the  nonpolar  amino  acid isoleucine (Bw4‐80I), and to a lesser extent the polar amino acid threonine, at position 77‐80  (Bw4‐80T)95,101.  East African populations  have  low  frequencies  of  the KIR3DS1 allele  and  high  frequencies  of  KIR3DL1  alleles  and  HLA‐B  with  the  Bw4  motif, particularly with an isoleucine at position 80, compared to other populations globally99. Similarly,  the  inhibitory KIR2DL2  and KIR2DL3  gene‐products  are  alleles  of  the  same locus  and  recognize  HLA‐C  group  C1  molecules.  They  show  a  more  balanced distribution,  but  favor  KIR2DL3  expression  in  East  Africa.  The  KIR2DL1  gene  is constitutively expressed across all populations, and the receptor it codes for recognizes HLA‐C  group  C2 molecules99.  Expression  of  KIRs  is  genetically  controlled102,  and  the role of self‐MHC molecules in NK cell KIR repertoire formation is controversial103,104.  In addition to the KIR repertoire, NK cells have a number of receptors that help activate and  regulate  the  functional  response  such  as NKp30,  NKp44  and NKp46.  NKp30  and NKp46  are  constitutively  expressed  on  NK  cells,  however  NKp44  requires  IL‐2 activation to be upregulated94. The NCR ligands are insufficiently characterized. CD161 is  a  C‐type  lectin‐like  receptor with  numerous  activating  and  inhibitory  genes  in  the mouse, however there is just one gene in humans with conflicting reports of inhibitory function85  and  activating  function94.  Others  report  the  lack  of  the  classic immunoreceptor  tyrosine‐based  inhibitory  motif  (ITIM)  or  charged  amino  acids necessary  to  transmit  an  inhibitory or activating  signal  respectively105. The  ligand  for CD161 is a non‐MHC lectin‐like transcript‐185. NKG2D is a well characterized activating C‐type  lectin  and  responds  to  cellular  stress  due  to  infection  or  transformation  by upregulation  of  stress  ligands  such  as MICA, MICB,  and ULBP1‐494.  Another  group  of receptors  on  the  surface  of  NK  cells  that  are  type  II  C‐type  lectin‐like  membrane proteins are  the NKG2 receptors and  include NKG2A, NKG2C, NKG2E and NKG2F  that form heterodimers on  the surface of  the cell with CD94105. NKG2A and NKG2C are  the genes  for  the  inhibitory and activating  form of  this  receptor  that  recognizes HLA‐E,  a 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non‐classical  MHC  molecule,  that  binds  the  leader  sequence  from  classic  MHC  and represents an indirect way in which NKG2A and NKG2C can monitor the expression of HLA‐A,  ‐B  and  –C molecules  on  the  surface  of  the  cell94.  NKG2A  is  associated with  a more  immature  NK  cell  phenotype  that  is  purported  to  have  less  cytotoxic  potential while  NKG2C,  the  activating  form,  is more  prevalent  on  cytotoxic  NK  cells94,however expression  may  be  stochastic105.  There  are  a  number  of  additional  receptors  that influence NK cell response but are not covered in this thesis.   
 
Figure 4. NK Cell Receptors (adapted from Vivier, E., et al., 2011)106. As NK cells mature,  they  lose  intensity of CD56 expression and gain CD16 expression along with  increased cytotoxic potential. These CD56dim NK cells have  less  inhibitory NKG2A and are fully mature effectors cells with their full complement of KIR receptors. Utilizing  expressed  receptors  and  in  conditions  where  activating  signals  outweigh inhibitory signals, NK cells are able to recognize and kill infected or malignant cells 91‐93. NK cells are able to lyse target cells through multiple mechanisms including transfer of cytotoxic  granules  through  the  immunologic  synapse,  Fas  ligand  (FasL)  mediated 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apoptosis,  and  antibody dependent  cellular  cytotoxicity  (ADCC)107. Our  recognition  of ADCC pre‐dates that of NK cells with early observations of “non‐immune” lymphocytes selectively  killing  targets  in  the  presence  of  target  specific  antibodies108,109.  In  1987, research  in  the  HIV‐1  field  showed  that  NK  cells  could  recognize  virus  infected  cells specifically  through ADCC109.  Interestingly,  this  innate  and adaptive partnership  gives FcγR bearing NK cells an adaptive  feature of antigen specific recognition. NK cells are also able to directly kill transformed or infected cells with specialized cytotoxic granules containing  perforin  and  granzyme,  a  process  known  as  natural  cytotoxicity.  The cytolytic  process  requires  cell  adhesion  and  activation  followed  by  an  intracellular reorganization  and  facilitated  movement  of  the  lytic  granule  to  the  immunologic synapse, transfer of the granules contents and detachment resulting in the destruction of  the  target  cell110.  Interestingly,  there  is  evidence  to  suggest  that  signaling  through different  activating  receptors  could  lead  to  discrete  molecular  pathways  involving enzymes  involved  in  vesicle  trafficking  (eg.  Rb27a),  or  proteins  involved  in  fusion  of cytotoxic granules  to  the cell membrane  (eg. Munc13‐4)  that ultimately  results  in cell directed cytotoxicity111. The importance of granzyme‐ and perforin‐dependent cytotoxic killing  can  be  observed  in  inherited  conditions  such  as  Wiskott‐Aldrich  syndrome, where mutations in the WASP gene results in lack of WASP expression. WASP is critical in  actin  reorganization  and  formation  of  the  immunologic  synapse  and  lack  of WASP results  in  severe  immunodeficiency110.  In  addition  to  death  mediated  by  cytotoxic granules,  the  death  receptors  such  as  FasL  and  tumor  necrosis  factor  (TNF)‐related apoptosis‐inducing  ligand  (TRAIL)  are  other  mechanisms  of  NK  effector  function. TRAIL,  also  known  as  Apo2  ligand  has  been  shown  to  be  upregulated  on NK  cells  in response  to  interferon and  is associated with  the clearance of certain  tumor cells and response to viral infections112. FasL is stored intracellularly and can be sequestered to the surface through ligation of CD161 and has been shown to support the elimination of RMA‐S tumor cells by perforin deficient murine NK cells113,114. Taken together, NK cells are  lethal  effectors  with  redundant  mechanisms  that  allow  for  the  control  of transformed or infected cells.  NK  cells  also  exercise  their  effector  function  via  the  production  of  cytokines  and chemokines.  CD56brightCD16‐  NK  cells  are  generally  considered  to  be  more  immature with  less KIR expression, more  inhibitory NKG2A and are functionally skewed toward immunomodulatory  cytokine  production.  The  immature  status  of  CD56brightCD16‐  NK cells  is supported by the fact these cells have longer telomere length,  indicating fewer cellular  divisions,  and  upon  cytokine  stimulation,  these  cells  can  differentiate  into  a more mature  CD56dim  NK  cell115.  CD56brightCD16‐  NK  cells  express  higher  amounts  of CD62L, a surface molecule allowing binding  to  the  luminal surface of high endothelial venules  (HEV)  and  further  trafficking  of  NK  cells  out  of  the  peripheral  blood116. Furthermore,  the  chemokine  receptor CCR7  is  found on  the CD56brightCD16‐  subset  at high  levels,  targeting  them  to  lymph  nodes117.  These  cells  also  express  high  levels  of CCR5, CXCR3, and CXCR4118. Interestingly, CD56brightCD16‐ NK cells are found in greater numbers in the secondary lymphoid tissue, constituting as much as 75% of the NK cells found in the lymph nodes, while approximately 15% are observed in the spleen and as few  as  5%  in  the  peripheral  blood119.  In  addition  to  the  location,  CD56brightCD16‐  NK cells are able to produce cytokines and chemokines more effectively than their CD56dim counterparts and are able to proliferate in response to low level cytokine stimulation85. 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Furthermore,  this NK  cell  subset  is  found  in  secondary  lymphoid  regions  that  have  a high concentration of DC and T cells whereby NK cells can respond and direct responses both through soluble factors and cell‐to‐cell contact120,121.  In summary, CD56brightCD16‐ NK  cells  are  a  unique  NK  cell  subset  preferentially  capable  of  modulating  immune responses  in concert with DC and T cells  in a non‐cytotoxic  fashion and subsequently influence the adaptive immune arm.  NK cells are classically considered an “innate” effector cell, but this definition may not be  entirely  accurate  as  more  is  learned  about  this  lymphocyte  subset.  Adaptive immunity, which will be addressed in the next section, is understood to involve antigen encounter and specific recognition by T and B cells, followed by a period of proliferation and  establishment  of  memory  cells  poised  to  act  upon  antigen  re‐exposure.  Until recently,  this  was  not  considered  a  trait  of  NK  cells.  Antigen  specificity  has  been demonstrated  in  murine  NK  cells  through  the  activating  Ly49H  receptor  in cytomegalovirus  (CMV)  infected mice,  where  a  preferential  expansion  of  Ly49H+  NK cells  resembles  the  clonal  expansion  observed  in  T  cells122.  Furthermore,  expanded Ly49H+ memory NK cells exhibit elevated function both with type 2 interferon (IFN)‐γ production  and  degranulation  measured  by  CD107a  after  ex  vivo  stimulation  with antibodies against Ly49H or with cells expressing the CMV protein m157123. Originally demonstrated  to be  relatively  short  lived with a half  life of 7‐10 days124, NK cells  are now believed to differentiate into longer lived memory cells and in the case of the CMV Ly49H+ NK cells, residing in both lymphoid and non‐lymphoid tissue that respond more readily  to  antigen  re‐exposure123,125.  In  addition  to  the  CMV  model,  new  evidence suggests  that  NK memory  cells  can  be  generated  to  a  wide  variety  of  antigens  from influenza, HIV‐1 and vesicular stomatitis virus in hepatic NK cells expressing CXCR6126. Human NK cells are able  to discriminate MHC molecules bound with specific peptides through  inhibitory KIR127‐131. Further characterization of  the crystal structure of HLA‐Cw3 peptide complex with KIR2DL2 shows that direct contact takes place at position 7 and 8 of the peptide and is contingent upon the amino acid residue at position 8 of the peptide within  the MHC class  I binding groove132. Collectively,  this data demonstrates that NK cells possess germline encoded antigen specificity and that certain populations of NK cells are able  to proliferate and establish memory‐like effector cells  in order  to respond to antigen re‐exposure, thereby suggesting that these cells possess both innate and adaptive like qualities. 
 
2.4 Adaptive immunity  The adaptive immune system consists of clonally expanded, “antigen‐specific” cells that are able  to  respond  to a highly  specific pathogen  sequence.  In 1965, Max Cooper and colleagues characterized a model of two lymphocyte lineages mediating different arms of adaptive immunity from experiments on White Leghorn chickens studying the effects of removing the thymus, the bursa of Fabricius, neither organ or removal of both on one day old hatchlings133. Max Cooper’s thymus dependent cells and bursa dependent cells were  later defined as T cells and B cells originating  from multipotent progenitor cells within the bone marrow, maturing in the thymus and bone marrow, respectively134. We now understand that the mediators of adaptive immunity are lymphocytes that undergo gene‐rearrangement  and  clonal  selection.  In  the  evolutionary  tree  of  life,  adaptive 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immunity appeared with  the arrival of  jawless vertebrates approximately 500 million years  ago  and  is  associated  with  assembly  of  variable  immunoglobulin  lymphocyte receptors135. However, vital components of the adaptive immune system are present in invertebrates  (reviewed  in  136).  In  fact,  homologs  to  recombination‐activating  gene (RAG)1 and RAG2, which mediate the gene‐rearrangement necessary for the generation of  B  and  T  cell  receptors,  can  be  found  in  purple  sea  urchins  (Strongylocentrotus 
purpuratus),  although  the  function  in  these  lower  invertebrates  remains  unclear137. Through millions  of  years  of  evolution,  adaptive  cells  have  developed  functions  that overlap,  complement  and  support  innate  immunity.  These  highly  specific  adaptive lymphocytes  upon  recognition  of  their  cognate  antigen,  respond  by  proliferation, production  of  cytokines  or  chemokines,  direct  killing  in  the  case  of  T  cells  and production of antibodies in the case of B cells. The complexity of antibodies and other soluble serum factors make up the humoral immune response, but the remainder of this thesis will focus only on the functions and phenotype of T cells.  Thymus‐dependent cells (T cells) are the effectors of cell‐mediated adaptive immunity and have a broad range of functions. The classical model suggests that T cells develop from  multipotent  stem  cells  giving  rise  to  hematopoetic  stem  cells,  the  common lymphoid progenitor cell, and eventual development of T cell progenitors released from the bone marrow to the thymus where T cells develop and mature although the exact nature of this process continues to be explored87,138. Not all T cells are dependent on the thymus for development as there is evidence for other T cell populations developing in the  gut,  such  as  murine  intraepithelial  T  lymphocytes,  but  these  cells  may  serve different  functions  and  mature  with  different  receptor  arrangements139.  T  cell progenitors  that migrate  into  the  thymus  undergo  a  highly  discriminatory  process  of clonal  selection and deletion where  less  than 5%  fully mature and migrate out of  the thymus140.  It  is within  the  thymic  environment  of  cytokines,  chemokines  and  stromal cells that T cell gene rearrangement, differentiation and T cell selection can occur. T cell progenitors  lack expression of  the molecules CD3 (the proxy marker of T cells), CD4+ (helper  T  cells)  and  CD8+  (cytotoxic  T  lymphocytes,  CTL).  As  the  progenitor  cells become committed to T cell differentiation,  the process of T cell receptor (TCR) gene‐rearrangement  takes place starting with  the β  chain V, D, and  J  segments  followed by proliferation, expression of both CD4 and CD8, and finally rearrangement of the α chain V and J gene segments resulting in the formation of the TCR 141,142. In addition to the αβ chain TCR, the γδ T cell results from the Vγ and Vδ chain rearrangement, however this population  is  far  less  frequent, does not go through the rigorous selection as does the 
αβ  T  cell  within  the  thymus  and  possesses  a  markedly  different  functional  and phenotypic profile that will not be reviewed in this thesis. The αβ gene rearrangement, from  the widely  diverse  V,  D,  and  J  segments,  gives  each  progenitor  a  highly  specific TCR. The total diversity of all TCR clones is on the order of 1018 resulting in an adaptive immune  system  with  the  ability  to  recognize  a  wide  variety  of  antigens75.  The CD4+CD8+ αβ TCR+ T cell progenitor goes through a complex selection process based on receptor binding strength to MHC‐peptide complexes, intracellular signaling through molecules such as lck and zap70, and in an IL‐7 dependent down selection of either CD4 or CD8 receptor  completing development143,144. These antigen naïve CD4+ T cells  and CD8+ T cells emigrate out of the thymus ready to survey circulation for antigen. 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Antigens derived from intracellular and extracellular material are presented to T cells through MHC class I and class II molecules, respectively. MHC class I molecules present small peptides, 8‐10 amino acids in length, to CD8+ T cells for a cell‐mediated immune response  that  includes  cytokine/chemokine  production  and  direct  cytotoxic  killing.  Intracellular  antigens,  both  host  and  foreign,  are  screened  to  monitor  infection  or altered self. Processing and presentation include proteolysis, folding and stabilization of the class  I molecule,  loading of peptide  fragments  into  the MHC complex,  followed by transport to the cell surface. Proteolysis involves targeting proteins, via ubiquitination, for degradation by the proteasome. The proteasome is made up of the 20S tube subunit and  capped  by  19S  subunits  on  both  ends  (reviewed  in  145).  Proteins  are  tagged, unfolded  and  inserted  into  the  inside  of  the  20S  cylinder where  the  catalytic  activity cuts the proteins in to small peptides. TAP1 and TAP2 are heterodimer complexes that actively  transport  these  peptide  subunits  from  the  cytosol  to  the  lumen  of  the  ER146. Once  inside  the ER, peptides are  loaded  into MHC class  I molecules and peptide‐MHC complexes  are  then  released  from  the  TAP‐tapasin  complex  and  transported  to  the surface  of  the  cell  for  presentation147.  Alternatively,  MHC  class  II  molecules  present peptides >12 amino acids in length to CD4+ T cells. Unlike the MHC class I presentation pathway,  MHC  class  II  antigens  are  classically  considered  to  be  exogenous  material including  foreign  pathogens.  Antigen  uptake  is  achieved  through  a  number  of mechanisms  such  as  macropinocytosis  and  phagocytosis.  Antigens  are  taken  up  into endocytic  vesicles  that  undergo  maturation  through  which  certain  reactive  oxygen species  are  generated,  pH  is  decreased  by  proton pumps,  and  activation  of  proteases allows  for  the  degradation  of  antigen  into  peptide  fragments148.  Mature  endocytic vesicles  containing  processed  antigen  fuse  with  MHC  class  II  loaded  vesicles  where peptides replace  the  invariant chain peptide and bind  into  the MHC class  II groove149. Interestingly,  additional  proteolytic  processing  of  the  peptide  can  occur  after  the peptide  is  loaded  into  the MHC  class  II  molecule  but  does  not  alter  the  amino  acids contained  within  the  groove150.  These  peptide  loaded  MHC  class  II  molecules  are transported to the cell surface and present the peptide to CD4+ T cells.   HLA  is  the  system  of  MHC  molecules  in  humans  and  the  genes  that  code  for  these molecules  can  be  found  on  human  chromosome  6.  The  human MHC  class  I  antigens include HLA‐A, HLA‐B and HLA‐C, while human MHC class II antigens include HLA‐DR, HLA‐DP, and HLA‐DQ. There is extreme allelic diversity  in the genes that make up the HLA system globally. For HLA class I there are 1519 HLA‐A, 2069 HLA‐B and 1016 HLA‐C  alleles,  and  for  HLA  class  II  there  are  969 HLA‐DR,  179 HLA‐DQ,  and  173 HLA‐DR alleles (from the IMGTT/HLA online database)151. The HLA class II molecules are more complicated because there are two chains, the α and β chains making up the functional portion  of  the  heterodimeric  peptide  binding  protein,  whereas  the  class  I  HLA functional  portion  is  derived  from  only  the  α  chain.  In  addition  to  the  major  class  I antigens,  there  are  three minor  HLA  antigens;  HLA‐E with  10  alleles,  HLA‐F with  22 alleles,  and HLA‐G with 46 alleles known151. The enormous diversity of both  the HLA class I and II alleles results in a varying ability to bind different peptides into the groove of the MHC molecule. In fact, the highest degree of variability in the MHC region occurs at  sites  that  affect  peptide  binding  into  the  MHC  molecule152.  This  may  account  for differential  ability  among  populations  in  protection  from  certain  diseases.  African 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populations possess  the greatest diversity  in  the MHC region, particularly HLA class  I molecules152.The polymorphic system of MHC class I and II in humans presents a wide range of peptides derived from “self” and “non‐self” to the cells of the immune system in order to direct an appropriate response.    
 
Figure 5. The yin and yang of cell mediated immunity.  Signaling  of  T  cells  through  their  TCR  by  HLA  presented  peptides  stimulates  a  wide array of  functions such as cytotoxicity,  immune modulation and regulation.  In normal healthy  conditions,  CD4+  helper  T  cells  outnumber  CD8+  cytotoxic  T  cells approximately  2:1  in  peripheral  blood  circulation.  CD4+ T  cells  play  a more  dynamic role in the immune system as they are integral in supporting B cells to make antibodies, enhance  CTL  killer  function,  regulate  and  suppress  aberrant  immune  responses,  and communicate  with  a  number  of  cells  in  the  immune  system  to  coordinate  efficient responses153.  Originally, CD4 cells were proposed to direct a bimodal immune response as shown in mice producing cytokines in responses to a number of antigens such as fowl g globulin and chicken red blood cells, where type 1 (TH1) was associated with IL‐2 and IFN‐γ and type 2(TH2) was associated with B cell stimulating factor 1 and T cell growth factor 2 (now known as IL‐4)154. In fact, the cytokine response that corresponds with a TH1 lineage is considered to be  involved in directing cellular activity while TH2 helper cells could be more involved in humoral support. The heterogeneity of CD4+ T cells  is now known  to  be more  complicated with  additional  lineages  identified  such  as  Th17, regulatory  T  cells  (Treg),  and  follicular  helper  T  cells  (Tfh)  which  all  possess  unique functional  qualities,  are  found  in  certain  tissues  and  have  distinct  phenotypes153. 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Furthermore,  CD4+  T  cells  have  been  shown  to  effect  cytotoxicity  through  granzyme and  perforin  release  in  an  MHC  class  II  dependent  manner155.  CD8+  T  cells  have  a slightly different process of differentiation and function. In the presence of proper TCR stimulation  and  costimulation,  a  CD8+  T  cell  will  turn  on  to  produce  cytokines  and chemokines  while  killing  target  cells  through  a  number  of  mechanisms  including directed cytotoxic granules and death receptors156,157. Further classification of CD4+ T cell and CD8+ T cell distinct  subsets can be made  through examination of  the diverse surface markers that correspond to different activation and maturational states. Some of these receptors will be reviewed in the next section.  
2.5 T cell receptors and functions Stimulation  of  naïve  T  cells  requires  a  combination  of  signals,  usually  first  involving ligation of  the TCR with corresponding peptide  loaded HLA molecule and  followed by co‐stimulatory signals through CD28 or other similar receptors found on the surface of the T cell in order to promote survival over apoptosis158. Some of the surface molecules involved  in  providing  co‐stimulation  include:  CD28,  inducible  T  cell  costimulator (ICOS)(CD278),  lymphocyte  function  associated  antigen  1  (LFA‐1)(CD11a/CD18), signaling lymphocytic activation molecule (SLAM), 4‐1BB (CD137), OX40 (CD134) and CD27  (all  reviewed  in  158‐160).  In  addition  to  co‐stimulatory  signals,  receptors  exist  to negatively  regulate  immune  responses  through  inhibitory  signals  such  as  cytotoxic  T lymphocyte  antigen‐4  (CTLA‐4)(CD152)  and  programmed  death‐1  (PD‐1)(CD279)159. PD‐1 is a 288 amino acid transmembrane protein with an ITIM and an immunoreceptor tyrosine‐based switch motif (ITSM) intracellular domain161. This inhibitory member of the  CD28  family  can  be  expressed,  especially  during  activation,  on  T  cells,  B  cells, natural  killer  T  cells  and  dendritic  cells161.  PD‐L1  and  PD‐L2  engagement  of  PD‐1  is thought to participate in balancing the immune response by down regulating activation.  PD‐1  co‐inhibition,  in  the mouse model,  is dependent upon  the  strength of  the PD‐L1 inhibitory signal, TCR engagement and CD28 co‐stimulation162. Furthermore, CD28 co‐stimulation and IL‐2 can overcome the inhibitory signal provided by the PD‐1 and PD‐L1  interaction162‐164.  In other  studies with primary human CD4+ T cells, PD‐1  ligation overrides  suboptimal CD28 co‐stimulation  resulting  in decreased  levels of  IL‐2,  IL‐10, IL‐13,  IFN‐γ,  and  the  anti‐apoptotic  protein  BcL‐xL  production  indicating  not  only compromised  function  but  decreased  cell  survival165.  The  amount  of  inhibitory receptors varies on murine CD8+ T cells and it is proposed that many of these receptors are expressed in a non‐redundant fashion suggesting that blocking the signal from one is sufficient  to restore normal  function164.   Through this combination of signals  that T cells receive, the dynamic nature of T cell responsiveness is formed.  In addition to co‐stimulatory and co‐inhibitory receptors, several molecules are  found on the surface of T cells and are associated with an “activated” phenotype. CD69 is a c‐type lectin found on the surface of recently activated lymphocytes, including T cells, and is associated with proliferation and Ca++  influx166,167. CD25  is  the  interleukin (IL)‐2 α chain  receptor  and  is  up‐regulated  12‐24  hours  after  antigen  activation  and  is associated  with  the  generation  of  the  high  affinity  IL‐2  receptor,  proliferation  and differentiation168.  Interestingly,  a  recent  report  by  Geldmacher  and  colleagues examining  co‐infection  of  mycobacterium  show  that  HIV‐1  preferentially  infects 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stimulated CD4+ T cells expressing CD25 on their surface169. Two additional activation markers that are relevant in HIV‐1 infection are CD38 and HLA‐DR170. HLA‐DR is a MHC class  II  molecule  and  has  been  shown  to  be  up‐regulated  48‐60  hours  after  antigen stimulation168. HLA‐DR is primarily  found on  immune cells and  is up‐regulated due to TCR stimulation in T cells or IL‐4 exposure in B cells171. Experiments conducted in vitro show macrophage expression of HLA‐DR can be down‐regulated due  to prostaglandin E2 while supernatant from mitogen activated T cells or purified IFN‐γ will up‐regulate class II molecules on macrophages and endothelial cells, which under normal conditions do not express class II molecules172. In vivo studies studying daily intraperitoneal IFN‐γ administration  in  mice  show  elevated  class  II  MHC  expression  widely  across  many tissues  such  as  heart,  kidney,  liver,  lung  and  spleen,  however  increases  were  not observed in lymph nodes173. Additional information is needed in order to elucidate the cause of  increased expression of HLA‐DR on T cells and the consequence of sustained periods  of  expression.  CD38  is  an  ectoenzyme  found  ubiquitously  on  the  surface  of immune cells and has been associated with states of activation  in T cells174. Originally identified  in  1980,  CD38  is  now  known  to  be  involved  in  a  number  of  functions including  catabolism  of  ADP‐ribose,  NAD+,  recruitment  of  Ca2+,  internalization  of nucleotides and chemotaxis to endothelial cells expressing CD31 (reviewed in 175). Hon Cheung Lee’s identification of similarity in sequence to the ADP‐ribosyl cyclase from the sea mollusk  (genus Aplysia)  allowed  for  the  critical  link  to  identify  enzymatic  activity and also marks the importance of this molecule as highly conserved through evolution where  enzymatic  homologs  are  found,  predating  humans  by  700 million  years176,177. The  significance  in  T  cell  activation  may  come  from  the  metabolic  demand  put  on proliferating  and  functional  cells  responding  to  antigen.  A  switch  from  oxidative phosphorylation  to  aerobic  glycolysis  gives more  products  necessary  for  growth  and survival178.  In  addition,  CD38  has  been  associated with  lateral  co‐localization  of  TCR, BCR  and  CD16  and  may  be  involved  with  the  metabolic  requirements  of  their signaling175. Examining these markers of activation individually or in tandem may help characterize aberrant forms of activation associated with certain diseases and identify potential targets to mitigate the response.  Maturation or differentiation of T cells is the process that occurs in CD4+ naïve or CD8+ naïve  cells  after  emigration  from  the  thymus  and  in  response  to  activation  by  their cognate antigen. This process is paired with proliferation and the generation of effector cells, effector memory cells, and long‐lived central memory cells. The precise pathway that T cells  take  to become memory cells  is not entirely understood, but a number of investigations  in  human  disease  and  vaccine  settings  have  characterized  some  of  the homing and phenotypic profiles that define discrete populations of memory cells. Some of  the markers used to  identify effector and memory cell subsets  include CD27, CD28, CD45RA, CD45RO, CD57, CD62L, CD127, and CCR7. CD45RA and CD45RO are isoforms of the protein tyrosine phosphatase receptor type C and are associated with naïve and effector populations on the CD45RA+ cells and memory populations from the CD45RO+ cells179. CD27 is a co‐stimulatory member of the TNF‐receptor family and engagement with  its  ligand,  CD70,  can  enhance  proliferation  and  cytokine  production160.  CD28  is another  co‐stimulatory  molecule  mentioned  above  and  both  CD27  and  CD28  are associated  with  less  antigen‐experienced  stages  when  expressed  on  the  surface  of  T 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cells. CD57 is a glycoprotein found on the surface of numerous cells, but on T cells has classically  been  associated with  replicative  senescence180.  The  IL‐7  receptor α  chain, CD127,  is  associated  with  a memory  phenotype  in  CD8+  T  cells  specific  for  vaccinia virus181. Finally, markers to characterize the homing potential of T cells are commonly used to differentiate cells. CC chemokine receptor 7 (CCR7) and L‐selectin (CD62L) are both  surface  receptors  that  allow  trafficking  through  high  endothelial  venules  and expression of these markers is associated with central memory and naïve phenotypes, but  is  poorly  predictive  of  effector  function182.  In  order  to  develop  vaccines  or  other interventions  that harness  subsets of T  cell  immunity, more  information  is needed  to elaborate  the model of T  cell differentiation and  the generation of  long‐term memory cells.  The adaptive  immune response has evolved mechanisms  to protect  the host  from the deleterious  effects of prolonged  inflammation or  self‐directed  responses. One method involves T cells with unique phenotype and function that have the ability to manipulate and  regulate  the  immune  response,  maintaining  immune  tolerance  and  avoiding inappropriate  immune  activation  and  autoimmunity.  These  cells  are  known  as regulatory T cells  (Tregs). Tregs develop  from T cell precursors  in  the  thymus or can be induced  under  certain  cytokine  environments  in  the  periphery.  They  can  regulate effector T cell responses through production of TGF‐β, IL‐10, IL‐35, granzymes, perforin and receptor mediated signaling (reviewed  in 183). Traditionally, Tregs  are  identified as CD4+, CD25+ and forkhead box protein 3 (FoxP3)+, however identification of these cells continues to be debated as other surface characteristics such as reduced CD127, the IL‐7 receptor, may be a better predictor of suppressor function in human CD4+ T cells184. FoxP3 is a transcription factor that has a role  in Treg  function, however  in cooperation with  other  transcription  factors  may  play  an  important  role  in  proliferation, differentiation,  and  cell  development185,186.  A  number  of  phenotypic  and  functional characteristics have been associated with discrete subsets of Tregs. For example, Tregs that are targeted to the skin will express αE integrin chains, CCR4, E selectin and P selectin. Regulatory responses targeted to TH1 effector T cells are through factors mediated by T‐bet,  a  transcription  factor  shared  by  both  the  IFN‐γ  producing  T  cells  and  Tregs183. Additionally,  Tregs  are  able  to  prevent  adaptive  immune  responses  through  cross  talk with dendritic cells, where Tregs expressing CTLA‐4 are able to prevent expression of co‐receptors CD80 and CD86 thereby preventing effective priming of a T cell response187.  There  are many more  phenotypic markers  that  are  associated with  the  function  and location of Tregs  indicating  that  these  cells have oversight of many  lymphoid and non‐lymphoid compartments.  The functional heterogeneity of T cells continues to be explored in relation to location throughout  the  human  body,  cell  phenotype  and  the  functional  profile  exhibited  in various  disease  conditions.  In  many  viral  infections,  production  of  certain  cytokines such as  IFN‐α,  ‐β,  ‐γ  and TNF‐α  have direct  anti‐viral  affects whereas other  cytokines such  as  IL‐1α,  IL‐1β,  IL‐2,  IL‐6,  IL‐12,  IL‐13  and  IL‐18  modulate  immune  responses indirectly188.  T  cells  are  potent  sources  of  IFN‐γ,  TNF‐α  and  IL‐2.  Chemokines  are secreted  proteins  that  are  involved  in  the  recruitment  of  immune  cells  to  sites  of inflammation  and  certain  chemokines  such  as  macrophage  inflammatory  protein 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3.2 Flow cytometry The first  flow cytometer patented in the US (US Patent 2,656,508)195 was put forth by Wallace  H.  Coulter  based  upon  a  system  that  could  quantify  microscopic  particles suspended  in an electrolyte solution and measured by electrical  impedance, a process known as the Coulter Principle196. Building upon the early counting chambers and the ability to distinguish simple characteristics of microscopic particle size was the ability to detect  fluorescence. The Herzenberg  lab at Stanford University was one of  the  first groups  to  successfully  discriminate  and  sort  cells  (mouse  splenocytes  from  Chinese hamster  ovary  cells)  based  on  the  intracellular  expression  of  fluorescein  and subsequent  light  emission  after  excitation  with  a  blue  laser197.  These  pivotal experiments led to the phrase fluorescence‐activated cell sorting (FACS), which to many is  synonymous with  flow  cytometry  and  remains  part  of  the  name  of  several  Becton Dickinson  BioSciences  flow  cytometry  instruments.  Second  generation  FACS instruments, in the 1980’s and into the 90’s progressed from measurement of size (light forward  scatter),  granularity  (light  side  scatter)  and  single  fluorescence  channel  to 3‐ and 4‐color  flow  cytometry using 1  and 2  lasers,  respectively.  The  ability  to measure multiple  parameters  at  the  single  cell  level  helped  immunologists  develop  a  better understanding  of  the  complex  nature  of  lymphocyte  phenotype  and  function, particularly  in T  cell  characterization. Toward  the end of  the 1990’s and  into  the 21st century, a rapid expansion in technology and reagents has witnessed 11‐color198,199 and up to 17‐color flow cytometry200. Moreover, the field of multi‐parameter flow cytometry beyond five to six colors has been termed polychromatic flow cytometry (PFC)201, and many labs have developed this capacity with a wide range of applications.  It is important to review the underlying technology of current flow cytometry in order to better understand  the hurdles  in PFC.  Immunofluorescently  labeled  cells  that have typically been fixed and are  in a buffered saline solution are acquired into the fluidics system of  the  flow  cytometer where  they  are  funneled  into  the  flow  cell.  In  theory,  a single  cell  line passes  through  the  flow  cell where up  to  three or  four  laser beams of varying intensity intersect and excite specific fluorescent markers on each cell, thereby emitting  various  wavelengths  of  light.  The  light  emissions  are  detected  by photomultiplier  tubes  (PMT),  then  translated  and  recorded  as  voltage  pulses.  These pulses are  then converted  in  to electrical signals, amplified and  finally stored  into  the computer software for real‐time or batched analysis. Each laser is designed to stimulate specific  fluorochromes  that  have  a  range  of  spectral  emission  requiring  coordination with specific PMTs. One of the major advancements in flow was the trigon and octagon orientation of the multiplier tube detector array in order to maximize different parts of the light spectrum. For example, the 633 nm red laser hits certain fluorochromes which each have a spectral range. The orientation of the trigon detector array (corresponding to the ability to detect up to three fluorescent signals) allows for the incoming light from the flow cell to be focused to the first PMT, “A”. In front of the PMTs sit a longpass filter and a bandpass filter. The longpass is rated at a specific spectral wavelength and allows all light of higher wavelength to pass while deflecting the light at lower wavelength onto the  second PMT  “B”. The  longpass  filter  in  front of  “B” passes  lower wavelength  light onto  the next PMT “C” and  in  the case of  the octagon detector array goes on  to up  to eight potential PMTs. The band pass filter is rated at a specific wavelength of a defined range and allows  light within  that  range  into  the PMT while deflecting  the  remaining 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Figure 9. Uganda BD FACS Canto II (3 laser configuration) used in PAPER III. One  of  the  major  challenges  in  leveraging  the  sensitivity  over  the  specificity  in  flow cytometry is the ability to correct for spectral overlap between different fluorochrome emissions, a daunting task known as compensation. In the silver age of compensation, this  was  a  manual  process  that  was  done  before  sample  acquisition  and  involved looking  at  individually  stained  fluorochromes  bleeding  over  into  other  channels  and subtracting  out  the  “false  positive“  emission  to  levels  at  or  below  auto  fluorescence. This  was  quite  manageable  at  three‐  and  four‐color  instances  of  acquisition  and analysis,  however  when  going  beyond  this  number  of  fluorescent  analytes,  manual compensation becomes impossible. Software has been developed to make this analysis possible and can be done before or after sample acquisition. PFC compensation  is not without limitations and classic flow analysis strategies need to be reconsidered, such as classic quadrant gating which may no longer accurately segregate discreet populations uniformly202.  Moreover,  newer ways  to  visualize  data  can  enhance  data  analysis  and 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4. AIMS OF THESIS The general aim of this thesis was to examine the role of cellular immune functions in chronic,  untreated  HIV‐1  infection  in  Uganda.  Originally,  we  sought  to  investigate phenotypic and functional qualities of T cells responding to HIV‐1 in relation to rates of disease  progression  in  natural  HIV‐1  infection.  We  were  also  interested  in  the frequency,  function, and phenotype of NK cells  in acute and chronic HIV‐1 infection in our Ugandan cohorts. The data on NK cells would be anlayzed in relation to the immune responses  detected  and  potential  associations  with  viral  subtype  and  disease progression determined. We also intended to investigate Tregs in acute and chronic HIV‐1  infection.  Original  plans  to  examine  acute  infection  prospectively  in  a  cohort  of individuals at higher risk to acquire HIV‐1 in Uganda were not pursued due to protocol delays. Through the conduct of these cohort activities our specific study objectives were developed as follows:  
Study  Objective  1:  PBMC  are  increasingly  being  used  to  monitor  cellular  immune functions  in  infectious  disease  and  to  assess  vaccine  efficacy.  We  established  the capacity to process and cryopreserve PBMC in the resource limited setting, and aimed to  define  parameters  to  ensure  the  quality  of  product  in  HIV‐1  infected  and  HIV‐1 uninfected participants. (PAPER I)  
Study Objective 2: NK cells are important innate cells that are involved in the first line of  defense  against  viral  infections.  However,  little  was  known  about  these  cells  in Ugandans. We aimed to characterize the phenotype and function of NK cells and subsets in HIV‐1  chronic  infection  and  search  for possible  correlates  of  viral  control  in HIV‐1 subtype A and D infection. (PAPER II)  
Study Objective 3: Chronic immune activation, especially in CD8+ T cells, is believed to be  an  important  component  of  HIV‐1  pathogenesis  and  predictor  of  disease progression. Immune exhaustion has also been proposed as an important factor in HIV‐1  associated  immune  dysfunction.  We  aimed  to  investigate  pathological  CD4  T  cell activation  and  exhaustion  in  infected Ugandans, with  a  focus  on  the potential  driving forces behind persistent immune activation. (PAPER III)  
Study  Objective  4:  Certain  KIR  and  HLA  combinations  have  been  associated  with favorable outcomes in HIV‐1 infection by genetic epidemiological analysis. We aimed to characterize the role of  inhibitory KIR and their cognate class  I  ligands  in shaping the repertoire  and  function  of  NK  cells  in  HIV‐1  infected  and  uninfected  Ugandans. Furthermore, we aimed to analyze these parameters in relation to disease progression. 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5. RESULTS AND DISCUSSION HIV‐1 infection in Uganda represents not only a major medical crisis but poses severe socioeconomic  implications  that  hinder  many  aspects  of  the  country’s  growth  and development. Major improvements to the health infrastructure have resulted in access to  ART  by many who  are HIV‐1  infected,  but  too many  challenges  remain  to  achieve universal access. Since  the  initial observations of HIV‐1 over  three decades ago, much has been learned about the virus and host  interaction, yet  immune control of HIV‐1 is incompletely  understood  and  more  information  is  required  for  development  of  a globally  efficacious  HIV‐1  vaccine.  Through  the  aims  of  this  thesis,  information regarding cellular immunology in chronic untreated infection with HIV‐1 subtype A and subtype D was obtained and presented in the attached manuscripts. In this results and discussion  section, major  findings will  be  put  into  context  of  the  current  epidemic  in Uganda.  This  section  is  divided  into  smaller  sections  discussing  the  importance  of processing and PBMC cryopreservation, NK cells in HIV‐1 infection, mechanisms behind T cell activation and finally speculating how ART may restore the innate and adaptive systemic immune dysfunction caused by persistent HIV‐1 infection.  
5.1 Importance of reproducible PBMC processing and analysis in resource limited 
settings  PBMC  isolation  and  cryopreservation  is  essential  for  studies  with  complex immunological questions. Most current HIV‐1 vaccines and natural history studies are critically dependent on the ability  to  isolate, cryopreserve and thaw PBMC samples of high quality. In PAPER I, we characterized the yield, viability, phenotype and function of PBMC  from HIV‐1  infected  and uninfected Ugandans  and outlined methods  to  ensure quality.  Use  of  Leucosep®  tubes  for  PBMC  separation  reduced  granulocytes  and platelets, while enriching for lymphocytes and monocytes. B cells exhibited a significant decrease  following  processing  and  cryopreservation  in  both  HIV-1  infected  and uninfected  subjects  but  all  other  major  lymphocyte  subsets  were  preserved  at comparable  rates.  Cryopreservation  did  not  appear  to  impact  function  as  specimens exhibited low background and responded to staphylococcal enterotoxin B (SEB) by IFN‐
γ and IL‐2 production. Long‐term cryopreservation of samples stored  for greater  than three  years  did  not  impact  yield  or  viability  regardless  of  HIV‐1  infection  status. We have  developed  a  comprehensive  internal  quality  control  (QC)  program  to  monitor PBMC processing in order to guarantee that these cells will be suitable for vaccine trial immunogenicity and natural history studies.  
5.1.1 Phenotype of cryopreserved PBMC  PBMC  processing  and  cryopreservation  can  impact  the  ability  to  assess  certain lymphocytes. In PAPER I, B cell frequencies were decreased in both HIV‐1 infected and uninfected volunteers,  indicating particular sensitivity of B cells to the PBMC isolation and cryopreservation process (PAPER I, Fig. 1D and 1E). Interestingly, we observed no difference  in T cell or NK cell distribution,  strengthening  the results generated  in  this thesis  project.  However,  more  recent  data  shows  that  NK  cell  processing  can  alter phenotype  and  function of  this  lymphocyte  subset. Naranbhai  and  colleagues  showed that exposure of NK cells to the rigors of PBMC isolation using ficoll and centrifugation marginally  alters  the  expression  of  activation  markers  (CD69  increased  and  CD38 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decreased)  and  chemokine  receptors  (CCR4  increased  and  CCR7  decreased)  as compared to whole blood  levels  in healthy women from South Africa207. Furthermore, they  showed  that  delays  in  processing  samples  (greater  than  8  hours)  can  result  in similar alterations in phenotype and may diminish the ability of NK cells to respond to phorbol‐12‐myristate‐13‐acetate  and  ionomycin,  both  by  degranulation  and  cytokine production207.  Consequently,  future  studies  examining  activation,  function  and trafficking of NK cells  should  consider  the effects of PBMC processing.  In our  studies, PBMCs were  processed within  8  hours  of  blood  collection,  and we  demonstrate  that high quality cryopreservation in a high throughput specimen‐processing laboratory can be achieved in the resource limited setting. Other groups have also shown that delays in PBMC  separation  can  result  in  deleterious  effects  such  as  activation  of  granulocyte populations  that  inhibit  T  cell  function208.  PAPER  I  outlines  methods  to  monitor contaminating granulocytes and  to  reduce possible  contamination  through  training of technical  staff  on  strategies  to  harvest  less  Ficoll  beneath  the  PBMC  layer,  where granulocytes are found (see Thesis Fig. 7B). In addition, methods to monitor processing time  and  other  quality  indicators  are  crucial,  particularly  in  settings where  clinics  or blood  collection  is  conducted  off  site  from  the  processing  center.  Unfortunately,  we were  unable  to  compare  cryopreserved  NK  cell  phenotype  or  function  to  freshly isolated  specimens  and  future  studies  need  to  assess  the  impact  of  processing  and cryopreservation on NK cell research.  
 
5.1.2 Function of cryopreserved PBMC  The  purpose  of  PBMC  cryopreservation  is  to  store  lymphocytes  and  monocytes  in  a sufficient  manner  to  allow  for  the  batching  and  post  study  analysis  of  samples, particularly  when  fresh  assays  are  not  feasible.  In  order  to  qualify  processing procedures,  downstream  functional  and  phenotypic  assays  should  be  conducted  in order to ensure effectiveness of preservation techniques. To that effect, in PAPER I we show simple ways to monitor the quality of PBMC separation/cryopreservation both by viability and post thaw yield, but also in functional  in vitro assays that detect cytokine production  by  intracellular  flow  cytometry  in  response  to  various  stimulation conditions  (PAPER  I,  Fig.  3A  and 3D).  Furthermore, we  demonstrate  that  long‐term cryopreservation  of  PBMC,  in  both  HIV‐1  uninfected  and  HIV‐1  infected  individuals, does not impact the quality or quantity of PBMC post thaw. Accordingly, the procedures used to process, store and thaw PBMC are adequate for the down‐stream immunology assessment that we performed in this thesis. Since the publication of PAPER I in Clinical 
and  Vaccine  Immunology,  additional  papers  have  been  published  regarding  optimal processing and storage conditions  for T cell based assays. Many processing centers  in the resource limited setting lack access to liquid nitrogen and the ability to store PBMC below ‐70°C. Weinberg et al.  report  that  longer storage of cells at  ‐70°C decreased  the post‐thaw viability and antigen specific ELISpot  responses  in both HIV‐1  infected and uninfected  study  participants,  although  qualitatively  ELISpot  responses  did  not change209. Another study looking at processing and storage factors that impact in vitro assays, showed that prolonged storage without agitation prior to PBMC processing can lead  to  decreased  ELISpot  responses  and  higher  background  in  tetramer  staining  by flow cytometry210. Poor PBMC processing technique and prolonged storage most likely leads to increased apoptosis and decreased quality of the PBMC product. A novel study to  test  the hypothesis  that  the  level  of  programmed  cell  death  after  cryopreservation 
 34 
could  alter  downstream  functional  assays  showed  that  the  presence  of  late  apoptotic cells  was  associated  with  decreased  ELISpot  values  in  response  to  viral  lysates  and peptides211. There are a few methods to reduce some of the potential negative effects of poorly cryopreserved specimens. For example, suboptimal cryopreservation can lead to clumping of cells post  thaw, a process  thought  to result  from excessive cell death and release of DNA. The use of DNAse minimizes clumping and does not affect lymphocyte assessment212.    
5.2 NK cells in HIV­1 infection NK  cells  are  innate  lymphocytes  that  play  a  significant  role  in  the  control  of  viral infections,  including  HIV‐1.  In  PAPER  II  we  examined  the  state  of  the  NK  cell compartment in Ugandans with untreated HIV‐1 infection in comparison with matched uninfected  controls  and  investigated  possible  associations  between  NK  cells  and markers  of  disease  progression.  The  function  and  phenotype  of  NK  cells  were investigated  using  9‐color  polychromatic  flow  cytometry  analysis  of  cryopreserved PBMC. Interestingly, low CD4 counts were associated with increased levels of IFN‐γ and degranulation in CD56bright NK cells. Also noteworthy, the results of this investigation of indicated that HIV‐1 infected Ugandans display elevated NK cell activity, despite the altered functional and phenotypic NK cell profile.    
5.2.1 NK cell normal distribution in Ugandans NK  cell  absolute  counts  and  percentages,  defined  as  CD45+,  CD3‐,  CD16  or  CD56+, CD19‐  cells,  are  a  standard  part  of  the  immunophenotyping  panel  used  to  assess  the lymphocyte  distribution  in  cohorts  we  work  with.  Clinical  phenotyping  panels  are processed  using  a  fresh  whole  blood,  lyse  no  wash  procedure.  In  developing  flow cytometry  reference  intervals  for  Ugandans,  we  analyzed  654  normal  healthy  adults (unpublished  findings)  and  found  that NK  cells  constitute  14%  (5  –  32%  reference interval of 95%) of lymphocytes in whole blood while absolute counts of NK cells varied substantially  (86  ‐  854  cells/µl).  Gender  differences  were  observed  with  women exhibiting significantly  lower NK cell  levels than men in both percentage and absolute counts  (12%  vs  15%  and  283  vs  341  cells/µl,  respectively)(both  P<0.001).  As  it  has been previously  reported  that NK cell  frequency  is elevated  in Asians as compared  to Caucasians213‐216, we were interested to compare any potential differences between this Ugandan population and other more characterized cohorts in the US and Europe where NK  cells make  up  a mean 13% of  lymphocytes  (95%  range  =  5  –  26%)  and  absolute counts  ranged  from  84  ‐  724  cells/µl.  No  statistically  significant  difference  was observed between these geographically disparate locations. We also found that NK cell frequency was similar to normal values reported in Kenya217 and Tanzania218.   
5.2.2 CD56negCD16+ NK cells in chronically HIV­1 infected Ugandans In PAPER  II we  identified  trends  in HIV‐1  infection where CD4+ T cells  are declining concomitant  to  increasing  viral  load. However, we  observed  that  the  overall  absolute counts of NK cells remain unchanged (see PAPER II, Fig. 1A). Despite the appearance of consistency  within  the  NK  cell  compartment,  when  looking  at  NK  cell  subsets  we observed differences suggesting alterations due to HIV‐1 infection. As mentioned in the introduction, NK cells can be divided into subsets based on the expression of CD56 and 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CD16 where the CD56brightCD16‐ phenotype is associated with cytokine and chemokine production,  the  CD56dimCD16+/‐  phenotype  is  associated  with  cytotoxicity,  and  the CD56negCD16+  profile  marks  an  aberrant  NK  phenotype  that  is  developed  in  HIV‐1 infection93,96,107,219.  Contrary  to  previous  reports,  our  data  would  suggest  that CD56negCD16+ NK cells are not anergic, but may display an altered functional profile. We see  that  MHCnull  K562  cell‐stimulated  PBMC  in  HIV‐1  infected  study  participants responded with increased degranulation and MIP‐1β production as compared to HIV‐1 uninfected individuals (see PAPER II, Fig. 3F). Moreover, unstimulated CD56negCD16+ NK cells exhibited an activated state with increased cytokine (IFN‐γ), chemokine (MIP‐1β)  and degranulation  (CD107a) expression (see PAPER  II,  Fig. 3F).  In  fact, NK cells generally displayed elevated production of  IFN‐γ, MIP‐1β, as well as CD107a  in HIV‐1 infected subjects (see PAPER II, Fig. 3). The ontogeny of CD56negCD16+ NK cells is still unclear, although there has been some recent focus on what is driving this phenotype in chronic infections such as HIV‐1. One current model suggest that CD56negCD16+ NK cells differentiate  from  CD56dimCD16+/‐  NK  cells,  and  may  represent  a  distinct  functional subset of NK cells with preferential function to produce antiviral chemokines96. The role of persistent viremia on the size of this subset is unclear, although it appears that higher viral  loads  are  associated  with  higher  frequencies  of  CD56negCD16+  NK  cells  thereby suggesting that viral burden leads to the altered phenotype and function of this NK cell subset220,221.  It  is  interesting  that  CD56negCD16+  NK  cells  express  low  levels  of  CCR7, HLA‐DR,  NKG2A,  intermediate  levels  of  CD57,  while  most  of  these  cells  express  the activation marker CD38 and  the β  chain of  the  IL‐2/IL‐15 receptor, CD122222.  In vitro assays  exploring  differences  in  CD56‐  and  CD56+  NK  cells  from  HIV‐1  infected participants  show  that  stimulation with  recombinant human  IL‐2  completely  restores CD56 levels after 21 days in culture with simultaneous increases in proliferation219. IL‐2 treatment  had  little  effect  on  activating  and  inhibitory  receptor  expression  and  was insufficient  to  restore  function,  as  measured  by  K562  killing219.  In  many  ways,  the expansion of CD56negCD16+ NK cells resembles the build‐up of terminally differentiated exhausted CD8+ T cells observed in the highly activated environment of chronic HIV‐1 infection,  but  this  model  does  not  completely  fit96.  Therefore,  more  information  is needed  to determine  if  CD56negCD16+ NK  cells  are  exhausted due  to persistent HIV‐1 antigen exposure,  or  if  this  aberrant phenotype  results  from a distorted maturational process.  
5.2.3 NK cell control of HIV­1 infected CD4+ T cells A model where high HIV‐1 viral load in chronic infection directly drives expansion and dysfunction of NK  cells  remains  to  be proven.  In  fact,  the direct  ability  of NK  cells  to recognize and kill autologous CD4+ T cells has proven difficult to replicate in vitro223,224. Inhibitory KIR molecules recognize changes in the level of MHC class I molecules on the surface  of  cells.  Matthew  Bonaparte  and  colleagues  showed  that  despite  a  major reduction  in  surface  expression  of  class  I molecules  on HIV‐1  infected  cells,  NK  cells were not able to lyse autologous in vitro infected CD4+ T cells223. The same authors later reported  that  in  uninfected  donors,  in  vitro  HIV‐1  infection  of  activated  and proliferating  autologous  CD4+  T  cells  reduced  expression  of  HLA‐A  and  HLA–B molecules, but did not alter the level of HLA‐C or HLA‐E224. In addition, blocking of the HLA‐C  and HLA‐E  interaction  released  the  inhibitory  signal  and  increased killing was 
 36 
observed,  suggesting  that  HIV‐1  alterations  and  down‐regulation  of  class  I molecules may  make  these  cells  more  susceptible  to  NK  cell  killing224.  In  addition  to  loss  of inhibitory  signals,  activating  signals  are  necessary  to  stimulate NK  cell  killing.  Jeffrey Ward et al. showed that ligands for NKp30 or NKp46 are not present on infected CD4+ T cells. However, several  ligands  for NKG2D are  induced  including ULBP‐1, ULBP‐2, and ULBP‐3225.  One  potential  mechanism  of  NKG2D  ligand  up‐regulation  is  through  the action of the HIV‐1 protein Vpr226. Moreover, Manuela and colleagues showed that HIV‐1 infected donor‐derived NK cells are only able to kill autologous endogenously infected CD4+ T cells through NKG2D mechanisms, while reduced NCR ligands and expansion of CD56negCD16+ NK cells  leaves many NK cells unable  to  respond effectively  to  infected CD4+  T  cells227.  Another  argument  would  suggest  that  NK  cell  dysfunction  is  a consequence  of  HIV‐1  burden,  but may  not  be  associated with  direct  control  of  viral load,  evidenced  by  comparing  immunologic  controllers,  ART‐suppressed  individuals and non‐controllers221. Still, other mechanisms exist whereby NK cells can contribute to control  and  elimination  of  CD4+  T  cells.  As  discussed  in  PAPER  II,  up‐regulation  of NKp44 ligands is associated with co‐receptor usage and inversely proportional to CD4+ T  cell  absolute  counts  in  infected  monkeys228.  Additionally,  NKp44L  expression  is induced  on  bystander  CD4+  T  cells  in  the  presence  of  soluble  gp41229.  Our  data  in 
PAPER  II  supports  a model  where  NKp44  could  be  associated with  CD4  elimination (see  PAPER  II,  Fig.  4A).  Irrespective  of  the  numerous  reports  of  how  NK  cells  can potentially limit viral load and or kill CD4+ T cells, more information is needed to better understand the mechanisms that are associated with control of virus. This may not be possible to determine through studies of chronically HIV‐1 infected individuals, as the immune pressure exerted by NK cells may have been escaped by the virus at this period in disease progression.  
5.2.4 KIR genotype, NK cell KIR phenotype and HLA­B Bw4 80I  Genetic association studies have implicated NK cells as major contributors to control of HIV‐1.  KIR  receptors  and  their  HLA  class  I  ligands  have  been  intensely  studied, particularly  in HIV‐1, because KIR  and HLA  genes are highly polymorphic  and  certain KIR‐HLA interactions could influence differences between individuals in HIV‐1 disease progression98,100.  The  two  KIR  genes  KIR3DL1  and  KIR3DS1,  which  are  alleles  of  the same locus, and the inhibitory and activating receptors they encode, are both associated with  slower  HIV‐1  disease  progression  when  found  in  combination  with  their  HLA ligand230‐233.  In  PAPER  II,  we  show  a  reduction  in  KIR2DL1  expression,  unchanged KIR2DL2/DL3  expression  and  an  increase  in  KIR3DL1  expression  in  certain  NK  cell subsets (see PAPER II, Fig. 2C ­ 2F). To better understand the role of KIR receptors in this cohort from Kayunga district, we analyzed KIR and the corresponding HLA‐ligands at  the  genetic  level.  Sequence‐specific  priming  (SSP)  real‐time  PCR  was  used  to genotype  for  KIR3DL1/KIR3DS1, KIR2DL2/KIR2DL3 and their HLA-class I ligands as 
previously described234. HLA­B Bw4 or Bw6 was determined, allowing the discrimination of Bw4 alleles having isoleucine or threonine at position 80 corresponding to KIR3DL1 ligands.  Similarly,  HLA­C  group  C1  or  C2  was  determined  because  these  are  KIR2 ligands.  The  results  are  presented  in PAPER  IV.  The presence  of HLA­B Bw4­80I was associated with elevated frequencies of KIR3DL1+ NK cells in chronically HIV‐1 infected Ugandans.  Furthermore,  a  positive  correlation was  observed  between  the  size  of  the 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KIR3DL1‐expressing NK  cell  subset  and  viral  load,  and,  importantly,  this  pattern was observed only in Bw4­80I+ patients.   Preferential expansion of KIR3DL1+ NK cells in the presence of HLA­B Bw4­80I may at first glance seem to support a model whereby this genetic combination provides some level  of  virologic  control. However,  our data may not necessarily  support  a beneficial relationship  between  expansion  of  the  KIR3DL1+ NK  cells  in  the  presence  of  certain 
HLA­B  alleles.  In  fact, we  see  a  positive  correlation  between HIV‐1  viral  load  and  the KIR3DL1+ NK cell frequency in the presence of HLA­B Bw4, which may indicate that this phenotype  is  associated  with  increased  viral  replication  in  chronic  HIV‐1  infection (PAPER  IV, Fig. 2A). HIV‐1  is known  to down‐regulate  the expression of MHC class  I molecules  (HLA‐A  and  HLA‐B)  on  the  surface  of  infected  CD4+  T  cells235,236,  which leaves these cells as potential NK cell  targets according to the missing self hypothesis. As mentioned  above,  an  additional  activating  signal  is  needed  to  stimulate  these  NK cells such as NKG2D ligands induced by, for example, HIV‐1 Vpr226. More recently, Vpu‐mediated down‐regulation of  the  receptor NK, T and B cell  antigen  (NTB‐A) has been associated  with  an  incomplete  activation  signal  that  results  in  reduced  NK  cell degranulation and  cytotoxic  ability237.  It  is  tempting  to  speculate  that  this  incomplete stimulation could result in expansion and proliferation of the KIR3DL1+ NK cell subset, while not providing sufficient  stimulation necessary  for killing of  the  infected CD4+ T cell  target. This  is highly speculative and would need to be tested. This model may be supported by data in mice where murine CMV (MCMV) infection was associated with a biphasic expansion of NK cells 122,238. The initial phase was associated with proliferation and production of  IFN‐γ  independent of  the activating KIR‐equivalent  in mice, Ly49H, while  the  second  phase  was  a  specific  Ly49H‐dependent  expansion122,238.  Another possible explanation for the expansion of KIR3DL1+ NK cells may involve the peptides that  bind  the  HLA‐B  Bw4  groove.  Lena  Fadda  and  colleagues  show  that  an  altered repertoire of peptides  in HLA‐C can disrupt  the  inhibition provided normally  through KIR2DL2 and KIR2DL3239. The same could be true for certain HIV‐1 peptides binding to HLA‐B alleles with Bw4 motifs, thereby reducing KIR3DL1 inhibition. Irrespective of the possible  mechanisms  of  expansion,  there  still  exists  the  issue  of  viral  control demonstrated by numerous genome‐wide association studies where KIR3DL1 and HLA‐B  Bw4  are  linked  to  lower  viral  load  and  slower  disease  progression98,230‐233.  It  is important  to note  that our  study  is  limited  in  that we are  looking cross‐sectionally  in chronic  untreated  infection.  Galit  Alter  et  al.  showed  a  preferential  expansion  of KIR3DL1+ NK cells and increased KIR3DL1 mRNA in individuals with Bw4 80I in acute infection. As we discuss  in PAPER IV,  it  is possible  that  the major protective effect of KIR3DL1 may be exerted early in HIV‐1 infection.  
5.2.5 Increased CD56dimNK cell polyfunctionality in HIV­1 infection In addition to the increased frequency of KIR3DL1+ NK cells, we observe that NK cells are more  polyfunctional with  regard  to  CD107a,  IFN‐γ,  and MIP‐1β  in  HIV‐1  infected patients as compared to uninfected people (PAPER IV, Fig. 3). We go on to show that the KIR3DL1+ NK cells in Bw4+ individuals are particularly responsive to K562 cells by production of  increased  IFN‐γ  and MIP‐1β  (PAPER  IV, Fig. 4). This data  is  consistent with a previous report showing that KIR3DL1 in the presence of the cognate HLA class I 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5.2.6 NK cell memory It is tempting to ask if the expansion of KIR3DL1+ NK cells may represent a sort of NK cell memory  in  humans,  similar  to what  has  been  reported  in  the MCMV model.  The activating Ly49H receptor recognizes the viral protein m157, a MHC class I‐like decoy molecule,  and has  been  implicated  in  "antigen‐specific" NK  cell‐mediated  response  to CMV infection243,244. In this model of NK cell memory, initial recognition of infected DCs through Ly49H is accompanied by inflammatory cytokines such as IL‐12, which in turn induce NK cells to secrete cytokines, mediate cytotoxicity, and proliferate to expand an effector  pool  ultimately  seeding  the memory  population125.  It  is,  however,  difficult  to relate the function of the activating Ly49H receptor in MCMV infection to the inhibitory receptor  KIR3DL1  in  HLA‐B  Bw4+  HIV‐1  infected  humans.  In  fact,  murine  inhibitory Ly49C/I+ NK cells are less protective than Ly49C/I‐ cells, both by adoptive transfer and depletion  studies,  suggesting  that  inhibitory  receptors  may  not  be  beneficial  in  this model245.  Cooper  et  al.  suggest  a  model  of  NK  memory  where  NK  cells  are  non‐specifically  activated  by  inflammatory  cytokines  and  these  NK  cells  in  addition  to producing cytokines and mediating pathogen control, can seed a population of memory NK  cells  with  higher  functional  potential  upon  restimulation246.  This  model  may  not sufficiently explain the expansion of KIR3DL1+ cells either. More information is needed to characterize  the phenotype and  function of memory NK cells  to better define  these subsets in chronic disease. As mentioned earlier, memory hepatic NK cells sensitized to HIV  antigen  express  CXCR6,  but  this was  determined  in  a murine model where mice were administered virus‐like particles expressing HIV‐1 antigen to measure memory126. This  needs  to  be  explored  in  humans,  but  may  prove  challenging  based  on  the compartment where these memory cells are normally distributed.   
5.2.7 NK cell relationship to HIV­1 disease progression in Ugandans Numerous  alterations  are  observed  to  the  NK  cell  compartment  in  Ugandans  with chronic  HIV‐1  infection.  These  changes  seem  to  be  independent  of  viral  subtype.  as determined  by  comparison  of  HIV‐1  subtype  A  and  D,  which  represent  the  most common strains found in Uganda. We see an altered distribution of NK cell subsets with an  accumulation  of  CD56negCD16+  NK  cells  and  decreased  CD56dimCD16+/‐  NK  cells. Surface  phenotype  is  changed  with  decreases  observed  for  the  inhibitory  receptors CD161, NKG2A, KIR2DL1 and decrease in the activating receptor NKp30 (see PAPER II, 
Fig.2). These quantitative and qualitative changes in the NK cell compartment may be due both  to viral antigen exposure and to  the overall  immune status  in HIV‐1 chronic infection.  The  phenotypic  and  functional  changes  found  in  PAPER  II  were  not associated with  viral  load,  and  occur  in  a  context where  overall  NK  cell  frequency  is directly proportional to CD4+ T cell counts (see PAPER II, Fig.1). Furthermore, several parameters were found to be inversely proportional to CD4+ T cell counts, particularly in  the CD56brightCD16‐ NK compartment. This  compartment  is  generally  considered  to be  less  mature  or  differentiated.  In  our  studies,  we  observe  that  HIV‐1  infection  is associated  with  significantly  higher  CD56brightCD16‐  NK  activity  in  response  to  K562 cells  with  increased  IFN‐γ  and  CD107a  (see  PAPER  II,  Fig.  3).  This  heightened functional capacity in CD56brightCD16‐ NK cells is inversely proportional to absolute CD4 counts,  suggesting  a  link  to  the  decay  of  the  immune  system.  Additionally,  the CD56brightCD16‐  NK  cell  subset  is  immuno‐modulatory,  suggesting  a  more  supportive 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role in the adaptive immune response through production of cytokines. CD56brightCD16‐ NK cells are found at higher frequency in secondary lymphoid tissue, areas rich in other immune  cells  that  help  direct  adaptive  immune  responses120.  It  is  interesting  to  note that  CD56brightCD16‐  NK  cells  are  particularly  adept  at  responding  rapidly  to  innate signals. Macrophages stimulated with LPS induce CD56brightCD16‐ NK cells to produce 6‐fold  higher  amounts  of  IFN‐γ  compared  to  CD56dimCD16+/‐  NK  cells247.  LPS  and  other microbial products can cross the compromised, CD4+ T cell‐depleted gut barrier. This contributes  to  increased  levels  of  immune  activation,  a  hallmark  of  chronic  HIV‐1 disease progression248. Furthermore, NK cells can exert anti‐HIV‐1 functions (including IFN‐γ)  in  a  CD4+  T  cell‐dependent  manner249.  NK  cells  modulate  DC  function  and maturation  in  a  contact‐dependent  manner  contingent  upon  TNF‐α  production. Moreover, DCs and NK cells provide direct feedback in a reciprocal manner, enhancing function and maturation of both cell types250.  Interestingly, we observe reduced levels of NKp30 expression in HIV‐1 infected compared to uninfected individuals (PAPER II, 
Fig.  2),  and  this  activating  receptor  has  been  shown  to  be  important  in  NK  cell recognition  of  DC251.  The  cytokine  environment  also  tightly  regulates  NK  cell function252.  Indeed,  this  data  may  suggest  that  a  delicate  balance  exists  between multiple  arms  of  the  immune  system,  and  the  alterations  we  observe  in  the  NK  cell compartment may be the combination of an imprint of chronic infection and a directed response to HIV‐1 viral load.  
5.3 T cell activation in chronic HIV­1 infection HIV‐1  infection results  in a state of persistent  immune activation  that  involves T‐cells and  is  characterized  by  increased  surface  expression  of  CD25,  CD38,  CD69,  HLA‐DR, β2microglobulin and neopterin174. The most common measures of activation in T cells are CD38, an ectoenzyme important to the metabolism of T lymphocytes, and HLA‐DR. The degree of  immune activation  for any HIV‐1  infected  individual  is widely variable, but during  chronic  infection  it  is  associated with  level of  viremia, CD4+ T  cell  counts, and  disease  progression253‐256.  In  addition,  striking  correlations  between  disease progression and immune activation suggested prognostic value of monitoring activation markers  for  patients  on  antiretroviral  therapy257,258.  It  is  thought  that  baseline activation  is  higher  in  HIV‐1  negative  Africans  due  to  endemic  infections  and  poorer living  conditions,  as  compared  to  HIV‐1  uninfected  people  in  Europe  and  North America259. Additionally, dampening of the immune response due to cellular exhaustion may play a role in loss of control of HIV‐1 viremia. PD‐1 (CD279), is a negative regulator of TCR signaling and T cell activation161. PD‐1 expression on HIV‐specific CD8+ T cells is associated with poor  function of  these cells and disease progression  260‐262.  In PAPER 
III,  we  examined  expression  of  CD38,  HLA‐DR  and  PD‐1  on  T  cells  in  chronically infected Ugandans from the rural district of Rakai. As expected, all three markers were elevated  on  CD8+  T  cells  when  comparing  HIV‐1  infected  individuals  to  uninfected community matched controls, both by frequency and mean fluorescence intensity (data 
not  shown).  Similar  increases  were  observed  in  CD4+  T  cells.  What  became  most notable, however, was the co‐expression of these three markers, particularly on CD4+ T cells,  where  HIV‐1  infection  was  associated  with  profound  increases  compared  to uninfected people (PAPER III, Fig. 1B). These cells were CD45RO+, CCR7‐, CD28+, with 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an  increased  frequency  of  Ki67,  indicating  these  cells  were  effector  memory  cells undergoing proliferation (PAPER III, Fig. 1C).  
5.3.1 CD4+ Deregulated Effector Memory T cells Tregs down‐regulate the immune response in both CD4+ T cells and CD8+ T cells263. Loss of Tregs due to HIV‐1 infection may be associated with the hyperimmune activation and subsequent  CD4  depletion  observed  in  natural  infection  264.  Some  of  the  markers commonly  used  to  identify  Tregs,  including  CD25,  CD127,  and  FOXP3,  were  used  to quantify these cells in the Rakai cohort. We observed a statistically significant decrease in frequency of Tregs in HIV‐1 infected subjects compared to HIV‐1 negative individuals (PAPER III, Fig. 2A). The frequency of Tregs was not associated with viral load or CD4+ T cell  counts,  but  was  inversely  proportional  to  the  level  of  CD38,  HLA‐DR  and  PD‐1 triple‐positive CD4+ T cells (PAPER III, Fig. 2B­D). This indicated that the phenotype of these activated CD4+ T cells represented a deregulated effector memory subset (CD4+ TDEM).  Interestingly,  the  frequency  of  CD4+  TDEM was  correlated  directly  to  viral  load and  inversely  to  CD4+  T  cell  absolute  counts  (PAPER  III,  Fig.  3A­B).  In  addition, individuals who had higher  levels of CD4+ TDEM cells  (defined as  frequency above  the median)  progressed  faster  to  AIDS  compared  to  those with  levels  below  the median (PAPER III, Fig. 3C). The initial positive correlation of CD4+ TDEM cells with HIV‐1 viral load suggests  that  this activated phenotype  is driven by viral antigen, or alternatively that increased immune activation may fuel viral replication. Moreover, a combination of events  that  challenge  the  immune  system  could  actually  contribute  to  the  systemic immune  activation  and  the  appearance  of  CD4+  TDEM  cells  that  are  highly  associated with disease progression.  
5.3.2 CD4+ TDEM cells and microbial translocation One primary driver of immune activation in HIV‐1 infection is thought to be microbial translocation  across  a  compromised  “leaky”  gut265.  The  premise  of  this  suspected mechanism is that mucosal CD4+ T cells are preferentially depleted early in acute HIV‐1 infection and are never  recovered,  allowing  for  increased permeability  across  the gut membrane  by  certain  microbial  components  like  LPS266,267.  Original  observations suggested that plasma levels of LPS are directly correlated with T cell activation in HIV‐1 infected patients266, even in HIV‐1 elite controllers where a more gradual depletion of CD4+ T cells is observed268. To support the role of microbial product translocation, the natural  simian  immunodeficiency  virus  (SIV)  infection  in  African  green  monkeys, mandrils, and sooty mangabeys provide insight into disease progression, where in the presence of high viremia and absence of cellular activation and peripheral markers of microbial translocation, monkeys do not progress to a diseased condition269,270. What is more,  African  green monkeys  that  are  given  LPS  display  increased  levels  of  immune activation and exhibit higher levels of viral replication, possibly due to increased levels of CD4+ T cell targets271. Other markers of microbial translocation include soluble CD14 (sCD14), endotoxin‐core antibodies (EndoCAb), and bacterial ribosomal DNA 16S (16S rDNA),  all  of  which  associate  with  T  cell  activation  in  chronic  HIV‐1  infection248,266. Monocytes,  when  activated  with  microbial  products  such  as  LPS,  will  release  sCD14 from the surface of the cell266,272. In PAPER III we observe elevated levels of sCD14 that are directly proportional to CD4+ TDEM cells (PAPER III, Fig. 5A), directly proportional to  viral  load  (PAPER  III,  Fig. 4C),  and  inversely proportional  to CD4+ T  cell  absolute 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counts  (PAPER  III,  Fig.  4B).  Together  this  data  supported  a  model  of  microbial translocation.  However,  we  did  not  observe  a  difference  in  the  rates  of  disease progression  between  individuals  with  high  levels  of  sCD14  compared  to  individuals with low levels of sCD14 (PAPER III, Fig. 4D), suggesting that maybe sCD14 is linked to immune activation but less associated with disease progression. It is important to note that  our  data  is  in  contrast  to  a  recent  report  where  plasma  levels  of  sCD14  were independently predictive of disease progression and mortality. In this report, although the difference in levels of sCD14 between groups was statistically significant, it did not appear to be biologically significant273.  Interestingly though in this study, LPS was not associated  with  disease  progression,  indicating  that  activation  of  monocytes  and shedding  of  sCD14  may  not  be  dependent  on  LPS273.  In  addition,  the  investigators compared  the  upper  quartile  and  lower  quartile  of  their  cohort,  while  we  compared levels above and below the median. Our study is in line with another longitudinal study, in  Uganda,  where  sCD14  levels  demonstrated  little  relationship  with  disease progression274. Interestingly, in the Macaca mulatta model, microbial translocation was determined not to be involved in disease progression, as levels of sCD14 and LPS were not different between animals who progressed fast or slow275. More studies are needed to examine the role of sCD14 in immune activation as this molecule may represent an independent marker of monocyte activation that is associated with T cell activation.  In addition to the sCD14 being cleaved from the surface of monocytes, LPS induces the production of IL‐6. Moreover, HIV‐1 infection is associated with increased plasma IL‐6 levels276,277. We observed elevated  levels of  IL‐6  in HIV‐1  infected  individuals  that are directly proportional  to CD4+ TDEM  cells  (PAPER  III,  Fig. 5B), weakly proportional  to viral  load  (PAPER  III,  Fig.  4G),  and  inversely  proportional  to  CD4+  T  cell  absolute counts  (PAPER  III,  Fig.  4F).  Unlike  sCD14,  we  observed  faster  rates  of  disease progression  in  individuals with  high  levels  of  IL‐6  compared  to  individuals with  low levels  of  IL‐6  (PAPER  III,  Fig.  4H),  indicating  that  IL‐6  may  be  linked  to  disease progression more  so  than  sCD14.  In  addition  to  LPS,  the HIV‐1  protein Vpr  has  been shown  to  induce  monocyte  production  of  IL‐6278,  indicating  a  potential  direct  link between  HIV‐1  viral  antigen  and  monocyte  activation  independent  of  microbial translocation. Furthermore, monocytes from HIV‐1 infected individuals were ineffective at  responding  to  LPS,  arguing  against  the  contribution  of  microbial  translocation products in driving immune activation279. IL‐6 has been shown to influence the survival and  proliferation  of  antigen  specific  memory  CD4+  T  cells  thereby  increasing  the effector memory pool (reviewed in 280) and increasing the availability of targets for HIV‐1 infection. In experiments supporting PAPER III, we were unable to induce CD4+ TDEM cells with soluble IL‐6 (data not shown). We also did not see any production of IL‐6 in the  T  cell  compartment  after  stimulation with  a  diverse  range  of  antigens  (data  not 
shown).  However,  the  long‐term  impact  of  IL‐6  exposure  on  the  T  cell  compartment cannot  easily  be  addressed  in  vitro.  Taken  together,  our  data  may  suggest  that  the impact of chronic HIV‐1 infection is parallel  in the monocyte and T cell compartments but are not directly linked. The question remains, if microbial translocation is a cause or consequence of HIV‐1 disease progression281. 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5.3.3 CD4+ TDEM cells driven by diverse antigens, innate and bystander activation In an attempt to identify the cause of the aberrant immune activation and accumulation of CD4+ TDEM cells, we stimulated cryopreserved PBMC with an array of antigens in vivo to examine the development of these cells. We observed that Candida, CMV, and other recall  antigens were  able  to  induce  this  phenotype  after  3‐6  day  stimulation  periods (PAPER III, Fig. 6A). We also observed that the CD4+ TDEM cells were enriched for virus (CMV and HIV‐1) specific cells using an intracellular assay to measure IFN‐γ and TNF‐α production  (PAPER  III,  Fig. 6C). We were, however,  surprised when we observed no difference  in  TCR  Vβ  distribution  in  the  CD4+  TDEM  cells  as  compared  to  the  overall CD4+ T cell compartment (PAPER III, Fig. 6D). This data would suggest that a diverse array of microbial antigens inclusive of, but not limited to, products translocating across the  gut membrane  can  induce CD4+ TDEM  cells,  but  the  relative  contribution  to HIV‐1 disease  progression  still  remains  unclear.  Other  mechanisms  of  immune  activation include innate production of IFN‐α and bystander activation. pDC are innate cells that are able  to produce  interferons  in response to viruses (reviewed  in 78).  It  is proposed that pDC are able  to  recognize HIV‐1  through TLR7 and respond with vigorous  IFN‐α production  that  may  mediate  immune  activation282,283.  In  fact,  Angela  Meier  showed increased frequency of CD38+CD8+ T cells in direct response to IFN‐α, after 20 hours in 
vitro  culture284.  In  the  murine  model,  repeated  stimulation  of  TLR7  using  receptor agonist  R848  lead  to  lymphopenia,  increased  inflammatory  cytokines  and  altered lymphoid architecture, which may resemble HIV‐1 immune activation conditions285. As mentioned  in PAPER III, we  tried  to  induce CD4+ TDEM cells  through stimulation with IFN‐α,  however  we  were  unable  to  generate  the  phenotype  associated  with  HIV‐1 disease progression (data not shown). We did not observe upregulation or  increased frequencies of CD38+ T cells indicating that we were unable to replicate the conditions where IFN‐α may contribute to development of CD4+ TDEM cells.   Bystander activation is the non‐specific activation and expansion of T cells in response to  an  infection  or  inflammatory  condition.  Early  investigations  into  the  extent  of bystander  activation  examined  groups  of  mice  challenged  with  a  number  of  viral pathogens in order to assess the extent of heterologous T cell activation286‐290. Stephan Ehl showed that bystander activation in mice both in vivo and in vitro was dependent on cytokines  such  as  IL‐2  but  not  type  I  interferons  like  IFN‐α286.  Interestingly  common gamma  chain  cytokines  like  IL‐2  have  been  associated  with  increases  in  PD‐1 expression291, as is observed on our CD4+ TDEM cells. Another group showed that murine bystander  activation was  dependent  on  IFN‐γ290.  In  non‐human  primates,  absence  of bystander  activation  was  associated  with  nonpathogenic  SIV  infection  in  sooty mangabeys292.  In  humans  during  primary  HIV‐1  infection,  CD8+  T  cells  specific  for multiple  viruses  including  Epstein‐Barr  virus,  CMV,  and  influenza  virus  up‐regulate CD38  directly  proportional  to  HIV‐1  viral  load293.  Furthermore,  bystander  activation was  associated  with  increased  levels  of  Ki67  in  primary  HIV‐1  infection293. Concordantly,  we  observe  an  expansion  of  HIV‐1  and  CMV  specific  CD4+  TDEM  cells. However,  our  data  is  from  chronic  infection  and CMV  specific  cells  outnumber HIV‐1 specific cells. In addition, we see increased Ki67 expression in CD4+ TDEM cells thereby supporting  a model  of  bystander  activation. Taken  together our data  from PAPER  III supports several proposed models of pathogenic immune activation, but unfortunately 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do  not  define  one  precise mechanism  that  is  responsible  for  the  generation  of  CD4+ TDEM cells. It is likely that the different proposed mechanisms are not mutually exclusive and  are  somehow  tied  together  both  directly  and  indirectly  leading  eventually  to immunodeficiency and disease progression. 
 
Figure 11. Hypothetical mechanisms behind development of CD4+ TDEM cells in chronic HIV­1 infection.  
5.3.4 Will CD4+ TDEM cells restore after initiation of ART? Studies of immune activation in HIV‐1 infected patients, initiating ART, have shown that levels  of  CD38  and  HLA‐DR  are  reduced  on  CD8+  T  cells  in  parallel  to  viral  load decline257,258. Several studies have shown that despite the positive relationship between viral  load and CD8+ T cell activation, CD4+ T cell recovery on ART is not predicted by residual levels of T cell activation294‐296. We have identified pathogenic activation in the CD4+ T cell compartment that is predictive of disease progression, but it is unknown if the  size  of  this  subset  will  contract  in  response  to  ART.  Consideration  of  the hypothetical causes behind the expansion of CD4+ TDEM cells may help predict the effect 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of ART on these cells. Wei  Jiang et al.  showed that bacterial 16S rDNA was associated with higher levels of CD8+ T cell activation and lower levels of CD4+ T cell restoration in response to ART248. This data suggests that  irrevocable damage to the GALT during HIV‐1  infection  can  limit  the  success  of ART,  and microbial  translocation may persist along with CD4+ TDEM  cells  despite  virologic  suppression. This  is  not  the  same  for  all mucosal  sites  as  the  lower  respiratory  tract  is  somewhat  spared  from  the  massive depletion  that  is  observed  in  the  GALT,  and  complete  CD4+ T  cell  restoration  occurs through proliferation of  the resident CD4+ T cell pools297. Microbial  translocation was shown  to  persist  in  a  South  African  cohort  with  ART‐controlled  viremia,  where reductions  in monocyte  activation  appeared  to  be  linked  to  virus272.  It  is  noteworthy that  IL‐6  levels  were  found  to  be  primarily  related  to  opportunistic  infections,  and sCD14 was primarily linked to LPS levels,  independently of HIV‐1 viral  load indicating that ART may not reduce certain aspects of immune activation272. Malaria is a common infection in East Africa that is treated with chloroquine. Shannon Murray and colleagues examined the affects of chloroquine treatment on viral  load and immune activation298. They showed that despite unaltered viral  loads, chloroquine reduced the  frequency of CD38+HLA‐DR+ CD8+ T cells and proliferation  in both CD4+ T cells and CD8+ T cells. Chloroquine  treatments  are  short  and  the  modest  levels  of  reduction  in  immune activation may  be  too  transient  to  have  therapeutic  effect.  Anuradha  Ganesan  tested atorvastatin,  a  drug  used  to  lower  cholesterol  and  has  known  anti‐inflammatory properties,  in  HIV‐1  infected  ART  naïve  individuals299.  Interestingly,  they  did  not observe any change in HIV‐1 viral loads, but did see some modest changes in activation markers  (HLA‐DR  and  CD38)  on  both  CD4+  T  cells  and  CD8+  T  cells299.  Yet  another study  showed  that  the  central  memory  and  naïve  T  cell  populations  were  highly predictive of  immunologic  response  to ART, and  that  the central memory CD4+ T cell populations  were  inversely  proportional  to  CD8+  T  cell  activation300.  The  data presented in this study is consistent with a model where cytokines such as IL‐7 support T  cell  homeostasis  and  could  be  involved  in  CD4+  T  cell  recovery.  In  fact,  the  IL‐7 receptor,  CD127  was  shown  to  be  a  major  determinant  of  ART  CD4+  T  cell reconstitution and was negatively associated with CD8+ T cell activation301. Moreover, CD4+ T cells, and not CD8+ T cells have been shown to be more responsive to IL‐7 and IFN‐α  in  chronic  HIV‐1  infected  patients,  and  this  may  in  turn  drive  increased activation, proliferation and CD4+ T cell depletion302. Our data indicate that HIV‐1 viral antigen is also a driver of immune activation.. Some HIV‐1 infected individuals are not able to reconstitute the CD4+ T cell compartment despite viral suppression on ART303. In  a  recent  study,  standard  treatment  with  the  addition  of  integrase  inhibitor raltegravir, had no impact on immune activation in PBMC or GALT, in individuals with incomplete  CD4+  T  cell  restoration304.  In  addition,  levels  of  immune  activation  are predictive  of  second  line  therapy  success  in  HIV‐1  patients  who  are  failing  first  line treatment indicating that activation305. Taken together, all this data indicates a complex interaction between the virus and the pathological immune activation that is associated with  HIV‐1  infection.  Investigations  of  rates  of  restoration  of  CD4+  T  cells,  and  the possible  reduction  of  CD4+  TDEM  cells,  on  ART  may  provide  crucial  insight  into  the specific mechanisms that are responsible for disease progression and treatment failure. 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6. CONCLUDING REMARKS More knowledge about the mechanisms of HIV‐1 pathogenesis and immune correlates of protection are needed. The HIV‐1 epidemic is of particular concern throughout sub‐Saharan  Africa,  where  the  majority  of  infections  are  still  found.  We  aimed  to characterize immune cell functions in Ugandans with untreated chronic HIV‐1 infection compared  to  healthy  individuals. We  examined  processing  parameters  to  ensure  the highest  quality PBMC  in order  to  assess  immune  responses. We next  investigated NK cells  in chronic untreated  infection  in order  to  identify  the phenotype and  function  in healthy  Ugandans  and  examined  alterations  to  NK  cells  attributed  to  HIV‐1.  We characterized  a  number  of  changes  to  surface  receptors  and  increased  frequency  of CD56negCD16+  NK  cells.  Functions were  also  altered.  Through  the  conduct  of  NK  cell interrogation,  increased  predominance  of  KIR3DL1+  NK  cells  were  noted  in  HIV‐1 infected  donors  who  expressed  HLA‐B  Bw4  80I.  Furthermore,  we  saw  increased functional capacity of KIR3DL1+ NK cells in these individuals. Finally, we explored the role  of  T  cell  activation  in  chronic  HIV‐1  infection.  We  observed  accumulation  of activated  CD4+T  cells  that  co‐express  CD38,  HLA‐DR,  and  PD‐1, which  represented  a deregulated  effector  memory  phenotype  and  levels  of  these  cells  predicted  disease progression. We showed that several mechanisms could explain the unique presence of these cells in HIV‐1 infection. Together our data show alterations to innate and adaptive arms  of  cellular  immunity,  and  may  aid  the  development  of  pharmacological interventions. Below are the more salient findings that make up the body of this thesis. It is important to note that we observed no differences between HIV‐1 subtype A or D infection in any of the parameters we have assessed.  
PBMC processing and analysis in resource limited settings: 
• High quality PBMCs can be reproducibly prepared and stored in a resource limited setting.  
• Lymphocyte  lineages cryopreserved well except  for B cells where reductions were observed in both HIV‐1 infected and uninfected individuals. 




• NK cell  counts  correlate  to CD4+ T  cell  counts but not  viral  load  in  chronic HIV‐1 infection. 
• HIV‐1 alters NK cell  subset distribution with  a  redistribution  to CD56negCD16+ NK cells and reduction in CD56dimCD16+/‐ NK cells 
• HIV‐1  alters  NK  cell  receptor  expression  with  decreased  inhibitory  receptors KIR2DL1, NKG2A, and CD161 and decreased levels of activating receptor NKp30. 
• HIV‐1  increases  NK  cell  function  in  unstimulated  and  K562‐stimulated  conditions and CD56negCD16+ NK cells are not anergic. 
• Changes  in  NK  cell  phenotype  and  function  correlate  with  CD4  T  cell  loss.  For example, CD4 counts were negatively correlated to function in CD56bright NK cells. 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• CD4+  T  cells  that  co‐express  CD38,  HLA‐DR,  and  PD‐1  also  exhibit  an  effector memory phenotype (CCR7‐, CD28+ and CD45RO+) and higher Ki67 expression. 
• CD38+HLA‐DR+PD‐1+  CD4+  T  cell  frequency  is  inversely  proportional  to  Tregs frequency indicating a deregulated effector memory phenotype (CD4+ TDEM cells). 
• CD4+ TDEM cell  levels are directly proportional to viral  load,  inversely proportional to CD4 T cell absolute counts and predict progression to AIDS defining events. 
• CD4+ TDEM cell  levels are directly proportional to sCD14 and IL‐6,  indicating a role for microbial translocation and innate activation in expansion of this subset. 
• CD4+ TDEM cells are generated  in vitro  to a variety of antigen stimulations and are enriched  for  viral  (CMV  and  HIV‐1)  specific  cells  stimulated  ex  vivo  using  ICS  to measure IFN‐γ and TNFα production. 
• Direct ex  vivo  CD4+ TDEM  cells  display  a TCR Vβ distribution  similar  to  the  overall CD4 compartment, suggesting these cells are specific for a diverse array of antigens. 
 
Future  Considerations:  The  above  work  represents  advancement  to  our  current understanding  of  the  immune  dysfunction  observed  in  chronic  HIV‐1  infection.  We would like to follow up this work in a number of areas: 1. PBMC  function  using  cryopreserved  samples  is  preserved,  but  the  extent  of preservation of antigen specific cells is not known. 2. NK cell phenotype and  function are anecdotally compromised  in cryopreservation, although we have never experienced problems with this. A more concentrated and focused effort should be made to address this. 3. CD56negCD16+  NK  cells  should  be  characterized  more  in  depth  regarding  their phenotype and function in HIV‐1 chronic infection, and after ART. 4. KIR3DL1+ NK cells should be explored in early acute infection, and before and after ART  initiation  to  examine  if  this  population  is  responding  to  HIV‐1  virus  and determine role if any in viral control. 5. CD4+  TDEM  cells  should  be  monitored  before  and  after  the  initiation  of  ART  to determine if this population restores after treatment initiation. 6. Mechanisms behind development of CD4+ TDEM cells should be further explored, and role  of  cell  associated  viral  load  and  bystander  activation  further  characterized, particularly in early acute infection where little information regarding the formation of these cells exists. 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7. Links  between  the  adaptive  and  innate  immune  compartments,  particularly between CD4+ T cells and NK cells should be explored to understand how these cells interact  to  control  viral  infections,  and  delineate  common  factors  that  generate elevated pathologically activated states. 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